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INTRODUCTION 
Hypertensive disorders of pregnancy are the most common medical 
disorders complicating pregnancy.  The incidence is continuously 
increasing due to unknown reasons and the overall incidence is 7 to 10% 
worldwide. One in every 100 to every 2000 pregnancy is complicated by 
Eclampsia. Pre-eclampsia and Eclampsia as a cause of maternal mortality 
and morbidity is increasing worldwide both in developing and developed 
nations currently the contribution being 15 to 20%(1). 
Hypertensive disorders of pregnancy is a spectrum of disorder 
which include chronic hypertension that antedates pregnancy and 
gestational hypertension or pre-eclampsia that is unique to human 
pregnancy.  It is still a poorly understood condition.  The clinical course 
is progressive and characterized by continuous deterioration that is 
arrested only by termination of pregnancy.  Hence the disease must be 
detected in early stage and managed appropriately for improved maternal 
and fetal outcome (1). 
Biochemical markers will enable prompt detection of high risk 
pregnancies and those who will develop clinically significant disease and 
hence the maternal and fetal outcome can be improved by enhancing the 
antenatal care to those target women. 
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Lactate dehydrogenase (LDH) is an intracellular enzyme which 
converts lactate to pyruvate and its elevated level indicates cellular death 
and leakage of enzyme from the cell. 
Increased levels of S.LDH is a marker of increased cellular death 
and is found in association with pre-eclampsia and Eclampsia (2, 3, 4). 
Estimation of S.LDH is a simple, minimally invasive and cheap  
biochemical test which though nonspecific is found to be highly sensitive 
and a reliable parameter in estimating the severity of the disease in in 
some studies(2, 3, 4). 
This study aims at quantitating  the extent of cellular death in terms 
of S.LDH in patients with clinical profile of pre-eclampsia and eclampsia 
and thereby using S.LDH as a marker of severity of the disease. 
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AIM & OBJECTIVES 
 
1. To compare serum LDH levels in the normal pregnant women and in 
women with Pre-eclampsia and Eclampsia in the antepartum period. 
2. To correlate the severity of the disease, with lactate dehydrogenase 
levels in serum of patients of Pre-eclampsia and Eclampsia 
3. To correlate the maternal and perinatal outcome with lactate 
dehydrogenase levels in serum of patients of Pre-eclampsia and 
Eclampsia 
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REVIEW OF LITERATURE 
Pre-eclampsia is a multisystem disorder affecting every organ in 
the body. 
DEFINITION 
According to the International Society for the study of 
hypertension in pregnancy (ISSHP), Hypertension is defined as a systolic 
pressure of ≥140mm Hg and diastolic pressure of ≥ 90 mm Hg measured 
on 2 occasions at least 6 hours apart within 7 days (5). 
A single Diastolic reading of >110 mm Hg is also considered as 
Hypertension (6) 
A rise in blood pressure of 30 mm Hg in Systolic or 15 mm Hg in 
Diastolic pressure from mid pregnancy values with absolute values 
<140/90 is no longer considered as diagnostic criteria for gestational 
hypertension or Pre-eclampsia as evidence does not show an adverse 
outcome for these pregnancies (7) (8) 
Edema is no longer used as diagnostic criteria because it is a 
common accompaniment of normal pregnancy (6). 
Proteinuria is absent in gestational hypertension and it is an 
essential criteria in the diagnosis of pre-eclampsia. Proteinuria of 1g/L 
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or more (2+ or more by dipstick) in at least 2 random urine specimen at 
least  6  hours  apart  or  >0.3 g in  24  hours  sample  is  considered  as  
significant pre-eclamptic level.(9) 
CLASSIFICATION 
The National Institute of Health (NIH) working group of the 
NHBPEP – National High Blood Pressure Education Program (2000) 
categorized hypertensive disorders of pregnancy into four types (9). 
1. Gestational hypertension 
2. Pre-eclampsia & eclampsia 
3. Pre-eclampsia superimposed on chronic hypertension 
4. Chronic hypertension 
GESTATIONAL HYPERTENSION 
Gestational hypertension is defined as hypertension (systolic 
pressure of ≥ 140 mm Hg and diastolic pressure of ≥ 90 mm Hg measured 
on 2 occasions at least 6 hours apart within 7 days) diagnosed for the first 
time during pregnancy after 20 weeks of gestation without associated 
proteinuria and BP returns to normal within 12 weeks postpartum(9) 
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PRE-ECLAMPSIA & ECLAMPSIA 
Pre-eclampsia is defined as Hypertension (systolic pressure of ≥ 
140 mm Hg and diastolic pressure of ≥ 90 mm Hg measured on 2 
occasions at least 6 hours apart within 7 days) diagnosed after 20 weeks 
of gestation with Proteinuria of 1g/L or more (2+ or more by dipstick) 
in at least 2 random urine specimen at least 6 hours apart or >0.3 g in 24 
hours sample. 
Eclampsia is the occurrence of generalized tonic clonic seizures 
in a pre-eclamptic woman that cannot be attributed to other causes. (9) 
PRE-ECLAMPSIA SUPERIMPOSED ON CHRONIC 
HYPERTENSION 
Pre-eclampsia superimposed on chronic hypertension is a condition 
defined by  
1. New onset proteinuria in hypertensive women after 20 weeks 
of gestation  
2. Sudden increase in Blood Pressure or proteinuria or 
thrombocytopenia in women with hypertension and proteinuria 
before 20 weeks of gestation.(9) 
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CHRONIC HYPERTENSION 
Chronic hypertension can be  
1. Hypertension diagnosed before pregnancy, 
2. Hypertension diagnosed before 20 weeks gestation, not 
attributable to Gestational Trophoblastic Disease or Multiple 
Pregnancy,  
3. Hypertension first diagnosed after 20 weeks gestation and 
persistent beyond 12 weeks postpartum.(9) 
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Fig-1. NHBPEP- Classification of hypertensive disorder in pregnancy 
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RISK FACTORS (10) 
v Age > 35 years 
v Primigravida 
v Primipaternity 
v Interval from last pregnancy > 10 years 
v Limited sperm exposure. e.g., Oocyte donation, Donor 
Insemination. 
v Obstetric Factors 
Pre-eclampsia or Gestational Hypertension in prior 
pregnancy 
Multiple Gestations 
Hydatidiform mole 
Hydrops fetalis 
Abnormal uterine artery Doppler at 18-24 weeks 
Chromosomal anomaly (Trisomy 13, Triploidy) 
v Family history of Preeclampsia 
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v Pre-existing medical disorders 
Hypertension 
Diabetes mellitus 
Obesity: BMI of 35 kg/m2 or more 
Renal Disease 
Vascular Disease 
Auto Immune Disease 
Thrombophilias 
Anti-phospholipid Antibody Syndrome 
Hyper homocystinaemia 
Sickle Cell Disease/ Sickle Cell Trait 
ETIOPATHOGENESIS 
The etiology is still largely unknown.  The following mechanisms 
contribute to the pathogenesis. 
1. ABNORMAL PLACENTATION (11) (12) (13) (14) 
Pre-eclampsia is a disease of the placenta and the fetus is required 
for the development of the disease. 
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Optimal placental development in normal pregnancy involves a 
process of controlled trophoblastic invasion extending from the decidua 
upto inner third of myometrium by extravilllous trophoblast.  
The endothelial lining and the muscular layer of the spiral arteries 
are disrupted converting the small caliber muscular arteries into large 
capacity low resistance vascular spaces 
The development of these uteroplacental vessels proceed in two 
stages: 
Stage 1 : Occurs before 12 weeks post fertilization upto the 
interface between decidua and myometrium  
Stage 2 :  Occurs between 12 and 16 weeks and involves invasion 
of intra-myometrial segments of spiral arteries. 
In women destined to develop Preeclampsia, the trophoblastic 
invasion is incomplete and shallow, the deeper myometrial arterioles do 
not lose their endothelial lining and musculo-elastic tissue and their mean 
diameter is half that of vessel in normal placenta resulting in reduced 
uteroplacental blood flow. 
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Fig-2. Two stage theory of preeclampsia 
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2. ENDOTHELIAL DYSFUNCTION & VASOSPASM (15) (16) 
This is caused by  
a) Decreased formation of endogenous vasodilators such as Nitric 
Oxide and Prostacyclin A. 
b)  Increased generation of vasoconstrictors such as Endothelin and 
Thromboxane. 
c) Increased sensitivity to angiotension II that alters the vascular tone. 
Biomarkers of endothelial dysfunction such as plasma fibronectin, 
thrombomodulin and factor 8 antigen are increased in pre-
eclamptic pregnancies. 
3. GENETIC FACTORS (19) 
Pre-eclampsia is a multifactorial polygenic syndrome.  These 
include 
v MTHFR gene affecting methylene tetrahydrofolate reductase 
v Factor V (Leiden) gene 
v AGT (Angiotensinogen) gene 
v HLA genes causing Immunological intolerance 
v NOS 3 gene affecting endothelial NO production 
v F2 (Prothrombin – Factor II) gene 
v ACE (Angiotensin Converting Enzyme) gene 
14 
 
 
 
Fig-3. Normal & abnormal placentation 
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4. PROANGIOGENIC & ANTIANGIOGENIC PROTEINS  
Pro-angiogenic factors are vascular endothelial growth factor and 
placental growth factor. Anti-angiogenic factors are soluble fms like 
tyrosine kinase 1 and soluble endoglin. 
Soluble FMS like tyrosine kinase 
SFlt-1 (Soluble FMS like tyrosine kinase) is a variant of receptor 
for placental growth factor (PGF) and vascular endothelial growth factor 
(VEGF). Increased levels of  SFlt-1 decreases the activity of 
Proangiogenic factors like PGF & VEGF. But SFlt-1 levels were 
increased only within 5 weeks before the onset of hypertension and 
proteinuria. (20). 
Soluble Endoglin  
Soluble Endoglin is a placenta derived molecule which causes 
decrease in endothelial NO dependent vasodilatation and it begins to rise 
after 20 weeks of gestation and rises more steeply in pre-eclamptic 
patients (19) 
  
16 
 
 
 
Fig-4. Role of antiangiogenic factors in the pathogenesis of 
pre-eclampsia 
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5. RENIN-ANGIOTENSION-ALDOSTERONE SYSTEM 
The refractoriness to Angiotensin II is lost as early as 18-22 weeks, 
several weeks before the onset of hypertension in women who are 
destined to develop preeclampsia later in gestation (20) 
6.  IMMUNOLOGICAL INTOLERANCE 
Extravillous trophoblast express reduced amount of HLA-G in 
early pregnancy destined to be pre-eclamptic. A lower level of messenger 
RNA for HLA-G has been noted in trophoblast  from preeclampsia than 
from normal pregnant patients (21) 
7.  OXIDATIVE STRESS 
It causes endothelial damage and interferes with nitric oxide 
production and prostaglandin balance. (22) 
Heme oxygenase is a negative regulator of SFlt-1 production and is 
found elevated in smokers which reduces the risk of preeclampsia in 
smokers.  
PATHOPHYSIOLOGY 
Preeclampsia is a multi organ disorder and the following systems 
are commonly involved in its pathophysiology 
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Fig-5. Role of soluble endoglin in the pathogenesis of pre-eclampsia 
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1. KIDNEYS 
Kidneys are the most commonly involved organ. Glomerular 
capillary endotheliosis is the characteristic change in the kidney.  Early 
focal segmental glomerular sclerosis is also seen in some of the pre-
eclamptic patients.  
Proteinuria is the hallmark and its quantity indicates the severity of 
the disease. 
Acute Renal failure due to acute tubular necrosis is rare in 
preeclampsia. 
Serum Uric Acid is elevated as a result of reduced GFR and 
increased trophoblast turnover and production of purines due to placental 
Ischaemia.  
Urinary Sodium concentration is elevated and urinary excretion of 
calcium is diminished because of increased tubular reabsorption. (6) 
2.  PLACENTA 
Increased incidence of infarct, hematoma, congested chorionic 
villi, proliferative end arteritis and degeneration are seen in placenta of 
preeclamptic women. Microscopic examination reveal increased syncytial 
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knots, cytotrophoblastic cellular proliferation, fibrinoid necrosis, 
endothelial proliferation, calcified and hyalinised villous spots. (23) 
3.  LIVER 
Characteristic features are Periportal hemorrhage in the 
periphery of the liver.  Increase in liver enzymes SGOT, SGPT and 
clinical jaundice may occur.  The small hemorrhages combine to form 
subcapsular hematoma which stretches Glisson’s Capsule causing 
epigastric pain which is a sign of impending eclampsia.(5) 
4.  COAGULATON 
These include thrombocytopenia and reduced levels of clotting 
factors. Thrombocytopenia < 1 lakh cells/mm3 indicate severe disease.  
Evidence of hemolysis in the form of elevated S. LDH, bizarre shaped 
erythrocytes, Schistocytes, Spherocytes and reticulocytes are seen in 
severe disease. (24) (25) 
5.  CARDIOVASCULAR SYSTEM 
Cardiac changes in Pre-eclamptic patients are increased afterload 
and hemoconcentration.  Hemoconcentration is due to generalized 
vasoconstriction that follows endothelial activation and leakage of plasma 
into interstitial space. (6) 
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6. BRAIN 
The most common finding in brain in preeclampsia is edema.  
Concurrent foci of infarct may also be present.  Cerebral hemorrhage 
should be suspected in older gravida with chronic hypertension who 
present with hemiplegia, focal deficits or coma. (26) 
Visual disturbances like scotoma, blurring of vision or diplopia 
arise from three potential areas 
v Visual cortex of occipital lobe 
v Lateral geniculate nuclei 
v Retina. 
MATERNAL COMPLICATIONS WITH UNTREATED SEVERE 
PRE-ECAMPSIA(27) 
v HELLP Syndrome (13.3%) 
v Abruptio Placenta (11.7%) 
v Pulmonary Edema (3.1%) 
v Thrombocytopenia / DIC (1.4%) 
v Acute Renal Failure (1.4%) 
v Adult Respiratory Distress Syndrome (1%) 
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v Hepatic rupture (1%) 
v Eclampsia (1%) 
v Others 
a. Cerebral Hemorrhage 
b. Cortical Blindness  
c. Sudden postpartum collapse 
FETAL COMPLICATIONS WITH UNTREATED SEVERE PRE-
ECLAMPSIA(27) 
v Fetal growth restriction (43%) 
v Intrauterine death (8.2%) 
v Preterm delivery and cardiovascular morbidity associated with 
low birth weight 
PREDICTORS & MARKERS OF PRE-ECLAMPSIA 
Many markers and predictors of pre-eclampsia have been proposed 
for early detection of high risk pregnancies to improve perinatal outcome. 
They can be  
· Clinical test 
· Biophysical test 
· Biochemical test 
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CLINICAL TEST 
GANTS ROLL-OVER TEST. 
This test is otherwise called Supine Pressor test. Elevation of 
diastolic blood pressure by atleast 20 mm Hg induced by having women 
at 28-32 weeks of gestation assume the supine position after lying 
laterally recumbent predicts gestational hypertension. (28). 
MEAN ARTERIAL BLOOD PRESSURE 
Mean Arterial Blood Pressure >90 mm HG between 18-26 weeks 
is a predictor of preeclampsia.(27)(29) 
ANGIOTENSIN SENSITIVITY TEST 
A women destined to get preeclampsia will respond to less than 
8ng/kg/min of an angiotension infusion due to an alteration in vessel wall 
refractoriness.  This test is done between 26-30 weeks. (28) 
PULSE WAVE ANALYSIS 
Stiffness in the finger arterial pulse acts as a predictor (27) 
AMBULATORY BP MONITORING 
Alterations in circadian BP variability in the first trimester predicts 
pre-eclampsia 
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BIOCHEMICAL TEST 
PLATELET VOLUME 
A mean platelet volume of more than 11 Fl at 28 weeks of 
gestation was found to be associated with subsequent pre-eclampsia and 
more over increased platelet turnover may be an early marker of pre-
eclampsia. 
SERUM FIBRONECTIN 
The level rises within 12 weeks in those women destined to get 
preeclampsia with a positive predictive value of 29% and negative 
predictive value of 98%. (30) 
URINARY KALLIKREIN EXCRETION 
Inactive urinary kallikrein-creatinine ratio of < 170 between 16 
and 20 weeks of pregnancy predicts future development of 
preeclampsia.(27)(31) 
Protein C inhibitor is decreased by kallikrein, which is elevated due 
to activation of intrinsic coagulation pathway. 
URINARY CALCIUM EXCRETION 
Preeclampsia is characterised by marked reduction in the fractional 
excretion of calcium leading to striking hypocalciuria due to increased 
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tubular reabsorption of calcium. Urinary calcium level of < 12 mg/dL is 
associated with a sensitivity of 91 % (27) 
RAISED SERUM β-hCG 
Β-hCG is increased by 14-20 weeks of gestation due to abnormal 
trophoblastic invasion and increased production by hypoxic 
trophoblast.(27) 
DYSLIPIDEMIA 
Elevated levels of triglycerides, free fatty acids and lipoproteins are 
predictors of preeclampsia. (27) 
SERUM URIC ACID 
Elevated serum uric acid is seen in the first trimester in women 
destined to develop preeclampsia.(27) 
BIOPHYSICAL TEST 
UTERINE ARTERY DOPPLER 
Uterine artery impedance between 18 and 26 weeks has been used 
as an early morning screening test for women at risk of preeclampsia.  
The presence of high systolic/diastolic ratio and persistence of diastolic 
notch may predict preeclampsia or IUGR. (27) (29) (32) 
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Fig-6. Normal uterine artery doppler 
 
 
 
 
                      Fig-7. Abnormal uterine artery doppler 
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TEST RELATED TO FETOPLACENTAL 
ENDOCRINE DYSFUNCTION(27) 
v Alpha feto protein 
v Estriol 
v Inhibin – A 
v Activin – A 
v Pregnancy associated plasma protein – A 
v Placental protein 13 
v Corticotropin releasing hormone 
OTHER MARKERS (27) 
v Platelet Count 
v P-Selectin 
v Neurokinin B 
v Anti-thrombin – III 
v 24 hours ambulatory BP monitoring 
v Soluble fms like tyrosine kinase 
v Endoglin 
v Leptin 
v D-Dimer 
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MANAGEMENT OF PRE-ECLAMPSIA 
Preeclampsia is an unpredictable disorder whose management 
depends on the gestational age and severity of the disease. The only 
definitive management is termination of pregnancy. Based on various 
parameters pre-eclampsia is classified into mild and severe as below. 
Table 1- Classification of Pre-eclampsia 
Parameter Mild Pre-eclampsia Severe Pre-eclampsia 
SBP (mmHg) 140 to 159 160 & above 
DBP (mmHg) 90 to 109 110 & above 
Proteinuria 
>1g/L to <3g/L 
2+ in dipstick 
>0.3g to <5g in 24hours  
3g/L  & above 
3+ & above in dipstick 
5g & above in 24hours  
Headache No Yes 
Oliguria No Yes 
Pulmonary Edema No Yes 
Thrombocytopenia No Yes 
Elevated S.Creatinine 
(>1.2mg/dL) No Yes 
Elevated S. 
Transaminase No Yes 
Severe IUGR No Yes 
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MANAGEMENT OF MILD PRE-ECLAMPSIA(6) 
Mild Pre-eclampsia can be managed on outpatient basis with rest 
and blood pressure monitoring at home and more frequent antenatal 
visits weekly  or  two  weekly  to  detect  any  signs  or  symptoms  of  
worsening at the earliest.   
The  use  of  anti-hypertensive drugs for mild pre-eclampsia is 
questionable. The main objective of treatment with anti-hypertensives is 
to reduce the risk of severe hypertension, Eclampsia and cerebrovascular 
hemorrhage.  
  There is loss of cerebral auto regulation and risk of cerebral 
hemorrhage once the mean arterial blood pressure reaches 150 mm Hg. 
The first line drugs are Labetolol, Nifedipine and alpha methyl 
dopa. Patients with mild Preeclampsia can be induced at 38 weeks of 
gestation.   
Pregnancy should be terminated earlier if there is progression to 
severe preeclampsia and Eclampsia and for other obstetric indications 
like IUGR.   
If pregnancy is terminated before 34 weeks, steroids are given for 
lung maturity. Labour can be induced vaginally if there are no obstetric 
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indications for caesarian section.  If the cervix is unfavourable, induction 
can be done with Dinoprostone Gel.  Artificial rupture of membranes and 
oxytocin acceleration can be done if the cervix is favourable.   
During labour continuous blood pressure monitoring, CTG 
monitoring and active management of third stage of Labour is followed. 
Mild pre-eclampsia if  untreated can progress to severe pre-
eclampsia at any time and therefore watchful expectancy should be the 
rule in all cases of mild pre-eclampsia. 
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Fig-8. Management algorithm of mild preeclampsia 
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MANAGEMENT OF SEVERE PREECLAMPSIA (33) (34) 
The management of Severe Preeclampsia according to gestational age is 
v < 24 weeks     - Stabilize the patient and terminate pregnancy 
v 25-33 weeks   - Expectant management with intensive maternal 
and fetal surveillance,  steroid therapy 
v > 34 weeks   -     Stabilize the patient with strict fetal surveillance 
and deliver 
Maternal Surveillance in Expectant Management of Severe Pre-
eclampsia (6) 
v Blood pressure daily 
v Urine albumin daily 
v Weight daily 
v Platelet count, Renal function and Liver Function twice 
weekly 
v History of imminent symptoms 
v Coagulation profile 
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Fetal Surveillance in Expectant Management of Severe Pre-
eclampsia (6) 
v Fetal Kick count daily 
v Non stress test – twice weekly 
v Amniotic fluid index twice weekly 
v Ultrasound to assess gestational age and growth 
v Umbilical artery Doppler 
Indications For Termination in a Case of Severe Pre-eclampsia 
Under Expectant Management (33) 
Ø Severe Intrauterine Growth Restriction 
Ø Non reassuring fetal heart rate 
Ø Oligohydramnios with AFI < 5 cm 
Ø Gestational Age of 38 weeks or greater 
Ø Platelet count < 1 lakh per mm3 
Ø Progressive deterioration of hepatic function 
Ø Progressive deterioration of Renal function 
Ø Suspected placental abruption 
Ø Imminent symptoms like headache, visual changes, vomiting 
Ø Eclampsia 
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In case of severe preeclampsia, 
ü Admit to the labour ward 
ü Complete fetal and maternal evaluation within 24 hours 
ü Start anti-hypertensives if systolic BP ≥ 160 mm Hg or Diastolic 
BP ≥ 110 mm Hg 
ü Use prophylactic Magnesium Sulphate to prevent or reduce the rate 
of seizures 
ü Inject steroids if less than 34 weeks to help speed the Infant’s Lung 
maturity 
ü Terminate pregnancy immediately if there is deterioration of 
maternal or fetal condition 
INTRAPARTUM MANAGEMENT (6) 
ü Hourly Blood pressure monitoring 
ü Urine output and signs of impending eclampsia should be looked 
for 
ü Continuous fetal heart monitoring 
ü Adequate pain relief by epidural analgesia to cut down 
catecholamine release and hypertensive response. 
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ü Continue magnesium Sulphate in cases of severe preeclampsia 
ü Indicate Caesarean Section if there is worsening maternal 
condition, non-reassuring fetal pattern, failed induction or other 
obstetric indications. 
ü Active management of third stage of labour by giving oxytocin 5 
units IV or 10 units IM to avoid post partum hemorrhage 
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Fig-9. Management algorithm of severe pre-eclampsia 
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ANTIHYPERTENSIVE THERAPY 
Antihypertensive therapy during pregnancy is a double edged 
sword. Uncontrolled blood pressure during pregnancy will lead to 
increased maternal morbidity & mortality at one end. On the other end 
liberal use of antihypertensives will lead to in utero exposure of the fetus 
to these drugs and reduced fetal perfusion due to decrease in the pressure 
at which maternal blood perfuses the placental villous spaces. This may 
adversely affect the fetal growth. Hence antihypertensive therapy should 
be initiated based on benefit risk ratio.(35) 
There are little controversies regarding the ideal blood pressure at 
which antihypertensive therapy should be initiated. Some studies support 
the start of antihypertensive at a diastolic pressure of 105 mm Hg and 
some at 100 mm Hg (5). Till date starting antihypertensive drugs at a 
systolic  blood  pressure  of  greater  than  or  equal  to  160  mm  Hg  or  a  
diastolic pressure of greater than or equal to 110 mm Hg is universally 
accepted. 
According to the current guidelines, antihypertensive treatment for 
blood pressure ranging from systolic pressure of 140 to 159mm Hg and a 
diastolic  pressure  of  90  to  109 mm Hg  is  to  maintain  a  target systolic 
blood  pressure  of  130  to  155  mm  Hg  and  a target diastolic blood 
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pressure  80  to  105  mm  Hg for women without any comorbid illness. 
Similarly target systolic blood pressure of 130 to 139 mm Hg  and a 
diastolic blood pressure of 80 to 89 mm Hg diastolic is to be achieved for 
those women with co-morbidities (36) 
Drugs that can used with little side effects and higher benefit risk 
ratio are 
1. Centrally acting adrenergic agonist (Alpha Methyldopa) 
2. Beta blockers 
3. Calcium channel blockers 
4. Hydralazine 
5. Alpha blockers 
6. Clonidine 
Drugs that are absolutely contraindicated for its teratogenicity are 
angiotensin converting enzyme inhibitors (ACE inhibitors). In utero 
exposure of the fetus to ACE inhibitors like enalapril will lead to growth 
restriction, oligohydraminos, prolonged hypotension, anuria and limb 
contractures. 
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ORAL PREPARATIONS 
ALPHA- METHYLDOPA 
This is the most commonly used drug. It is a centrally acting alpha 
adrenergic agonist. Predominantly it acts on the central nervous system 
with little peripheral action. It decreases the sympathetic tone and arterial 
blood pressure by stimulating alpha 2 receptors. 
It can be started with 250 to 500 mg orally two to three times a 
day upto a maximum dose of 2g. The drug effect is maximum at 4 to 6 
hours and the duration of action is 10 to 12 hours.  
Side effects are headache, dryness of mouth, swelling of feet, 
depression, postural hypotension. Rare incidences of hemolytic anemia 
and hepatitis have been reported,  
The drug  crosses the placenta, reaches the fetus and is also 
secreted in breast milk. But long term follow up did not show teratogenic 
effect with these drugs and hence considered safe during pregnancy. 
BETA BLOCKERS 
Labetalol which is a combined alpha and beta blocker is  now  
becoming the first line therapy because of its higher efficacy and safety. 
Dosage is 100 to 400 mg twice daily. 
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Side effects are bradycardia, dizziness, nausea, vomiting, fatigue 
and depression. Care should be taken when used in patients with diabetes 
on insulin because beta blockers mask the warning signs of hypoglycemia 
in them. 
Other beta blockers that can be used in pregnancy are metaprolol, 
acebutolol and propanolol. The beta blocker that is contraindicated during 
pregnancy is atenolol because it causes intra uterine growth restriction, 
hypoglycemia and hyperbilirubinemia in the fetus. 
CALCIUM CHANNEL BLOCKERS 
Nifidipine is the commonly used drug and it is available as 5-10 
mg capsules or tablets. Dosage can be from 10 to  20  mg three  to  four  
times a day. Extended release tablets have been formulated to avoid the 
more frequent dosing and they have slower onset and a more prolonged 
action. Maximum dose of Nifidipine is 120 mg per day. Action starts in 
10  to  15  minutes.  Oral  dose  of  10  mg  can  be  repeated  every  30  to  60  
minutes to achieve the desired range of blood pressure. Nifidipine can 
also be administered sublingually but oral route is preferred because of 
the precipitous fall in blood pressure with sublingual route. 
Nifidipine when used along with magnesium sulphate will result in 
exaggerated hypotension because of their synergistic action in blocking 
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calcium channels. Also there are high chances of postpartum hemorrhage 
with the combined use of both due to the same reason. 
Side effects of nifidipine are flushing, headache, ankle edema, 
nasal congestion, heart burns, nausea, hypotension and palpitations. 
DIURETICS 
Diuretics cause depletion of intravascular volume. Since the 
placenta does not have an autoregulatory mechanism, placental perfusion 
is dependent on the maternal plasma volume and systemic pressure. Intra 
vascular volume depletion can severely compromise placental perfusion 
which is already compromised in pre-eclampsia. Hence diuretics are 
contraindicated in pre-eclampsia and intra uterine growth restriction with 
reduced placental perfusion proved by Doppler. 
Indications for diuretics in pregnancy are  
1. Congestive cardiac failure 
2. Acute pulmonary edema 
3. Cerebral/ Intracranial tension 
4. Renal failure 
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Fig-10: DRUGS USED IN PRE-ECLAMPSIA AND ECLAMPSIA 
 
(a). Tablet Nifedipine:    (b). Injection Labetalol: 
      
 
(c). Injection Magnesium Sulphate:  (d). Injection Hydralazine: 
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INTRAVENOUS PREPARATIONS 
Intravenous Preparations are used in hypertensive emergencies 
with a high blood pressure (systolic blood pressure greater than 160 mm 
Hg and diastolic blood pressure greater than 110 mm Hg) to avoid 
complications like cerebrovascular hemorrhage, hypertensive 
encephalopathy, eclampsia, congestive cardiac failure, placental 
abruption etc. 
LABETOLOL 
This combined alpha and beta blocker lowers the blood pressure 
smoothly and rapidly. Dosage is 10 to 20 mg bolus IV. This can be 
repeated every 30 minutes upto 80 mg till a maximum dose of 300 mg is 
reached. This can also be given in a continuous infusion form of 1 to 2 
mg/ minute. 
It takes five minutes for the onset of action and the peak action is 
obtained within 10 to 20 minutes of its administration. 
Side effects are maternal and neonatal hypotension and 
bradycardia. 
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HYDRALAZINE 
Hydralazine can also be administered as a bolus intravenous drug 
at 5mg every 20 to 30 minutes and infusion  at the rate of 0.5 to 10 mg 
per hour upto a maximum of 30 mg. It takes only 10 minutes to act. 
Side effects are headache, anxiety, restlessness and hyperreflexia. 
It causes tachycardia in contrast to labetolol which causes bradycardia  
Magee LA etal 2003 compared hydralazine with nifidipine for the 
treatment of severe hypertension. They reported that hydralazine was 
found to have higher incidences of hypotension, placental abruption, 
oliguria, low apgar scores and adverse fetal outcome.  
Low apgar scores and adverse fetal outcomes associated with 
hydralazine are due to the release of noradrenaline by the drug which is a 
potent vasoconstrictor of the uteroplacental circulation. This can be 
overcome by correction of hypovolemia & administration of intermittent 
small doses. 
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NITROPRUSSIDE 
Nitroprusside, a  potent vasodilator of arterial and venous smooth 
muscle is short acting and highly effective, given as  intra venous 
infusion at 0.25 μg/ kg/ minute to start with and can be increased to a 
maximum of 8 μg/ kg/ minute. 
It takes less than 1 minute for the onset of action and acts only for 
1 to 3 minutes. The main adverse effect seen with nitroprusside is cyanide 
toxicity to the fetus. 
ECLAMPSIA 
Eclampsia is defined as the development of Generalised Tonic 
Clonic Seizures that cannot be attributed to other causes and unexplained 
coma during pregnancy or puerperium in a woman with preeclampsia. It 
can be classified into 
v Antepartum 
v Intrapartum 
v Postpartum 
v Late Postpartum 
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COMPLICATIONS (6) 
The complications of Eclampsia could be maternal and fetal as 
follows 
MATERNAL 
v Maternal injury 
v Abruptio placenta 
v Aspiration pneumonia 
v Status eclampticus 
v Pulmonary edema 
v Cardiopulmonary arrest 
v Acute Renal failure 
v Disseminated Intravascular Coagulation 
v Coma 
v Maternal death 
FETAL 
§ Fetal bradycardia 
§ Hypoxic Ischaemic Encephalopathy 
§ Intrauterine death 
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MANAGEMENT OF ECLAMPSIA 
Eclampsia is a life threatening complication of pre-eclampsia 
which has to be addressed with zero delay.  
Management of Eclampsia is a team work involving an 
Obstetrician, Anesthetist, Physician and a Neurologist. 
The four main key components of management of Eclampsia are 
· Immediate resuscitative measures 
· Antihypertensives 
· Anticonvulsants 
· Obstetric management 
Clearing the airways – With the patient in left lateral position, 
airway should be cleared of any secretions and vomitus to reduce the risk 
of aspiration.(6) 
Control of seizures – The protocol for magnesium sulphate 
administration is as follows: (37) 
LOADING DOSE  
4g of 20% magnesium Sulphate is given IV slowly over 5 
minutes followed by intravenous infusion of 1g hourly (or) 10 g of 50% 
48 
 
solution intramuscularly (5g in each buttock) with 1 mL of 2% 
Lignocaine in the same syringe. 
MAINTANENCE DOSE   
5g of Magnesium Sulphate (50% solution)  with  1  ml  of  
Lignocaine 2% in the same syringe every 4 hours into alternate buttock. 
Continue the treatment with Magnesium Sulphate for 24 hours 
after delivery or after the last fit whichever is later. 
Magnesium Sulphate Toxicity is monitored with respiratory rate, 
patellar reflexes and urine output.  
Repeat doses of Magnesium Sulphate must be withheld or delayed 
if 
· Respiratory rate is < 16 per minute 
· Patellar reflexe is absent 
· Urine output is < 30 mL/hr over the preceding 24 hours. 
In case of respiratory arrest 
· Give Calcium Gluconate 1g (10 mL of 10% solution) slow IV 
until respiration is satisfactory 
· Assist ventilation using bag and mask, anesthetic apparatus or 
intubation 
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Control of Blood Pressure : 
Parenteral anti-hypertensives such as IV labetalol can be 
administered in uncontrolled hypertension.(6)(27) 
General Care and Fluid Care : 
Ringer Lactate solution is administered at the rate of 60-125 ml/hr 
after calculating the fluid loss.  Diuretics should be avoided unless there 
is evidence of pulmonary edema.(27) 
Termination of pregnancy : 
The definitive management of Eclampsia is termination of 
pregnancy irrespective of the gestational age. 
Patient must be delivered within 24 hours in case of Severe 
Preeclampsia and within 12 hours in case of Eclampsia.   
Mode of delivery is planned based on the obstetric indication.(6) 
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HELLP SYNDROME 
HELLP Syndrome is a life threatening complication of severe 
preeclampsia usually occurring during the later stages of pregnancy or 
sometimes after childbirth characterized by(38) 
ü Hemolysis 
ü Elevated Liver Enzymes 
ü Low Platelet count. 
The diagnosis of HELLP Syndrome is based on either of the two 
criterias namely Mississippi and Tennessee criterias. A set of blood 
investigations is required to diagnose HELLP  syndrome based on the 
above criteria and it includes complete blood count, coagulation profile, 
liver enzymes, renal function test, serum electrolytes and serum LDH. A 
positive D-Dimer test in the presence of pre-eclampsia was reported to 
predict HELLP syndrome.(39) 
PATHOPHYSIOLOGY 
The inciting factor is abnormal vascular tone, vasospasm and 
microvascular endothelial damage leading to intravascular platelet 
activation and coagulation defects. Activation of platelets result in the 
release of thromboxane A2 and serotonin, causing further vasospasm, 
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platelet agglutination and aggregation and endothelial damage. This 
cascade is only terminated with delivery.(40) 
MISSISSIPPI DIAGNOSTIC CRITERIA  
This diagnostic criteria was proposed by The University of 
Mississippi in 1999 & alternative classification was introduced in the year 
2006. 
Table 2- Mississippi Diagnostic Criteria 
Parameters Criteria 
Hemolysis 
v Serum Bilirubin >1.2 mg/dl 
v Lactate Dehydrogenase >600  IU/L 
v Progressive Anemia 
Elevated liver enzymes 
v AST ≥ 40 IU/L 
v ALT ≥ 40 IU/L 
Low Platelet Count 
v Platelet Count < 1,50,000/mm3 
v Alternative Classification 
· Class 3: 100,000 to 150,000/mm3 
· Class 2: 50,000 to 100,000/mm3 
· Class 1: <50,000/mm3 
 
Prothrombin time, partial thromboplastin time and fibrinogen level 
are usually normal in HELLP syndrome(41) 
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Table 3- Tennessee Diagnostic Criteria 
Parameters Criteria 
Hemolysis 
v Serum Bilirubin >1.2 mg/dl 
v Lactate Dehydrogenase >600 IU/L 
v Peripheral Smear 
· Schistocytes 
· Burr Cells 
· Helmet Cells 
Elevated liver enzymes v AST ≥ 70 IU/L 
Low Platelet Count v Platelet Count < 100,000/mm3 
 
DIFFERENTIAL DIAGNOSIS 
The differential diagnosis of HELLP syndrome include acute fatty 
liver of pregnancy, thrombotic thrombocytopenic purpura, hemolytic 
uremic syndrome, viral hepatitis, gall bladder diseases, gastroenteritis, 
kidney stones, pyelonephritis, encephalopathy and hyperemesis 
gravidarum. 
SYMPTOMS 
v Epigastric / Right upper quadrant pain 
v Nausea/Vomiting 
v Headache / Malaise 
v Visual changes 
v Jaundice 
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COMPLICATIONS OF HELLP 
ü Placental abruption 
ü DIC 
ü Acute Renal Failure 
ü Severe Ascites 
ü Cerebral Edema 
ü Pulmonary Edema 
ü Wound Hematoma 
ü Subcapsular Liver Hematoma 
ü Liver rupture 
Women with history of HELLP syndrome in the previous 
pregnancy is at a high risk of developing pre-eclampsia in the present 
pregnancy and the risk is estimated to be about 20%.(42) 
MANAGEMENT OF HELLP 
· Deliver rather than expectant management for pregnancies more 
than 34 weeks 
· For pregnancies less than 34 weeks, deliver after a course of 
steroids 
· Other modalities in HELLP syndrome are antithrombotics, 
Dialysis, Plasma exchange with FFP & Plasmapheresis(6) 
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Fig-12. Abnormal CT showing a subcapsular hematoma in a woman 
with HELLP syndrome 
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Fig-13. Management algorithm of HELLP syndrome 
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PREVENTIVE MEASURES OF PRE-ECLAMPSIA 
· Collaborative  Low  Dose  Aspirin  Study  in  pregnancy  (CLASP) 
studied the role of low dose aspirin in pregnancy for the prevention of 
pre-eclampsia. . 
The study showed a non-significant reduction of 12% in pre-
eclampsia but there was a significant reduction of proteinuric pre-
eclampsia in women prone to develop early onset pre-eclampsia .The 
only drug recommended for prevention of pre-eclampsia is low dose 
aspirin in some women at high risk of developing the disease (43) 
· Calcium supplementation with  1.5  to  2g  of  Calcium  carbonate  or  
elemental calcium from various preparations has shown to reduce the 
incidence of pre-eclampsia almost by half.(44) 
· Pharmacological agents such as Low molecular weight Heparin, 
Progesterone, nitric Oxide donors, anti-hypertensive medication and 
diuretics are not effective in preventing pre-eclampsia(6) 
· No correlation was observed between dietary salt intake and risk of 
pre-eclampsia(45) 
· The effects of rest, physical activity or exercise in the development 
of pre-eclampsia are still not clearly understood.(6) 
· The effect of Zinc and antioxidants supplementation are 
controversial.(6) 
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LACTATE DEHYDROGENASE 
Systematic Name: L-Lactate NAD+ Oxidoreductase(46) 
It catalyses the interconversion of Lactate and pyruvate. LDH is 
100 times more in RBC than in plasma. (46) 
 
Fig-14. Reaction catalysed by LDH 
 
 
LDH has  5  distinct  isoenzymes  (LDH 1,  2,  3,  4,  5).  They can  be  
separated by electrophoresis (cellulose starch gel, agarose gel).  LDH1 has 
more negative charge and fastest in electrophoretic mobility while LDH5 
is the slowest. (47) 
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STRUCTURE OF LDH ISO-ENZYME 
LDH is an oligomeric (tetrameric) enzyme made up of four 
polypeptide subunits.  Two types of subunits namely M (muscle) and H 
(Heart) are produced by different genes.  M Subunit is basic while H 
subunit is acidic.  The isoenzymes contain either 1 or both subunits 
giving LDH1 to LDH5. (46)  
M Subunit is encoded by LDH-A located on chromosome 11p15.4. 
  H subunit is encoded by LDH-B located on chromosome 12p12.2. 
A  third  isoform  named  LDH-C  or  LDH-X  is  expressed  only  in  
testis encoded by chromosome 11p15.5. 
Preeclampsia causes increase in total LDH. 
LDH-1 (H4) is predominantly found in heart muscle and is 
inhibited by pyruvate – the substrate.  Hence pyruvate is not converted to 
lactate in cardiac muscle but is converted to acetyl CoA which enters 
Citric Acid Cycle.  It has high Km (low affinity) for pyruvate and acts 
well in aerobic conditions 
LDH-5 (M4) is mostly present in skeletal muscle and inhibition of 
this enzyme by pyruvate is minimal and hence pyruvate is converted to 
lactate.  It has low Km (high affinity) for pyruvate and acts well in 
anaerobic conditions. 
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Fig-15.  Structure of LDH iso-enzyme 
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Table 4 - Sub Types of S.LDH 
 
Type Subunit Electrophoretic mobility 
Activity at 
600 for 30 
mins 
Tissue % in serum 
LDH1 H4 Fastest Not destroyed Heart 30% 
LDH2 H3M Faster Not destroyed RBC 35% 
LDH3 H2M2 Fast 
Partially 
destroyed Brain 20% 
LDH4 H1M3 Slower Destroyed Liver 10% 
LDH5 M4 Slowest Destroyed 
Skeletal 
muscle 5% 
 
 
Normal values of LDH 
· Non pregnant adult - 115 to 211 IU/L 
· First trimester – 78 to 433 IU/L 
· Second trimester -80 to 447 IU/L 
· Third trimester – 82 to 524 IU/L 
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Fig-16.  Conditions with increased LDH 
 
 
LDH is decreased with high doses of Vitamin-C 
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STUDIES ON LDH IN PREGNANCY 
· S.P Jaiswar, Amrit Gupta and Mohan Shaili at CSSM, 
Lucknow studied S.LDH levels in 146 women with 39  
normotensives, 35 mild pre-eclamptics, 36 severe pre-eclamptics 
and 36 Eclamptics and stated that LDH levels were significantly 
elevated in women with pre-eclampsia and Eclampsia (p<0.001), 
high blood pressure (p<0.10) as well poor maternal and perinatal 
outcome.(48) 
· Similar  studies  were  done  by  S.M. Munde, N.R. Hazari, A.P. 
Thorat, S.B. Gaikwod & V.S. Halolkar to examine the possible 
role  of  S.GGT  &  S.LDH  in  the  prediction  of  severity  of  pre-
eclampsia. The study comprised of 40 pre-eclampsia and 40 
normotensive pregnant controls. S.LDH levels were found to be 
significantly elevated in mild pre-eclamptic women (p<0.05) and 
severe pre-eclamptic women (P<0.001)(3) 
· He S, Bremme K, Kallner A and Blomback M studied Lactate 
Dehydrogenase as a predictor for the birth of small for gestational 
age infants. The study included 26 normotensives and 51 pre-
eclamptic women. They stated that pre-eclamptic women with 
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SGA infants had significantly higher LDH concentrations than 
those in the appropriate for gestational age group(2). 
· Qublan et al studied S. LDH levels of 171 women with 49 mild 
preeclamptic, 62 severe preeclamptic & 60 nomotensive women. 
He compared S. LDH levels with systolic blood pressure, diastolic 
blood pressure, uric acid, uric albumin & liver enzymes and found 
a significant correlation between them.(4) 
· Bakskandeh et al studied S. LDH in 50 preeclampsia & 50 
normotensive women & stated that LDH level was not statistically 
different between healthy and preeclamptic women.(49) 
· A study on LDH profile as a retrospective indicator of uterine 
preparedness for labour were done by Jeremy et el. They stated 
that more efficient cervical dilatation following labour admission is 
associated with a more anaerobic maternal S.LDH profile in post 
delivery period.(50) 
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STUDY DESIGN 
Observational Study 
METHOD OF STUDY 
This study involves the measurement of S.LDH in a total of 173 
antenatal patients of gestational age 28weeks and above. 
INCLUSION CRITERIA 
v Group 1 = 50 Normotensives (Controls) 
v Group 2 = 123 Hypertensives (Cases) Including   
· Mild Pre-eclampsia –BP of 140/90 to < 160/ 110 mmHg 
· Severe Pre-eclampsia –BP ≥ 160/ 110 mmHg 
· Eclampsia – One or more episode of GTCS 
attending antenatal OPD/ Labour ward in Chengalpattu Medical College 
Hospital during the period of  November 2013 ~ August  2014. Patients 
were selected based on inclusion and exclusion criteria after obtaining 
their consent (Annexure II). A detailed history, clinical examination and 
all necessary investigations were done. (Annexure IV) 
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EXCLUSION CRITERIA 
1. Mothers with hypertension at < 20 weeks gestation, 
2. Preexisting diabetes mellitus, 
3. Renal disease, 
4. Liver disorder 
5. Thyroid disorder 
6. Epilepsy 
7. Heart disease 
8. Muscular dystrophy 
9. Leukemia 
10. Pernicious Anemia 
11. Hemolysis and other causes of increased LDH 
12. HIV reactive women 
13. Meningitis 
METHOD OF LDH ESTIMATION 
1 ml of venous blood sample was taken under all aseptic 
precautions. It was then allowed to clot and then centrifuged for serum 
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separation. Estimation of S. LDH is done by International Federation of 
Clinical Chemistry (IFCC) method. 
Assay: Crest Biosystems 
Principle: 
Lactate dehydrogenase catalyses the reduction of pyruvate with 
NADH to form NAD. 
Total LDH is tested by reaction of serum sample with lactate and 
NAD.   
L + Lactate + NAD+ à Pyruvate + H+ + NADH 
NADH has absorbance maximum at 340 nm. The optimal 
conditions for the reaction are temperature of 30 ± 0.05⁰C and pH of 9.40 
± 0.05.  After  a  definite  time  NADH  is  used  up  by  the  reaction  and  the  
decrease in absorbance will be proportional to enzyme activity detected 
by spectrophotometer.  
Sample material: 
Serum free from hemolysis. Total LDH is reported to be stable in 
serum for 1-3 days at 2-8⁰C. Freezing inactivates the liver isoenzyme. 
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Procedure: 
Wavelength/ filter : 340nm 
Temperature  : 30⁰C 
Light path  : 1cm 
Substrate Start Assay: 
Pipette into a clean dry test tube labeled as Test (T): 
Addition Sequence Temp= 30⁰C 
Buffer Reagent 
Sample 
0.8ml 
0.05ml 
Incubate at the assay temperature for 1minute and add 
Starter Reagent 0.2ml 
 
Mix well and read the initial absorbance A0 & repeat the 
absorbance reading after every 1, 2 & 3 minutes. Calculate the mean 
absorbance change per minute (∆A/min.) 
Sample Start Assay: 
Pipette into a clean dry test tube labeled as Test (T): 
Addition Sequence Temp=30⁰C 
Working Reagent 1.0 ml 
Incubate at the assay temperature for 1 minute and add 
Sample 0.05ml 
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Mix well and read the initial absorbance A0 & repeat the 
absorbance reading after every 1, 2 & 3 minutes. Calculate the mean 
absorbance change per min (∆A/min.) 
Calculations: 
Substrate / Sample Start 
LDH Activity in U/L (30⁰C) = ∆A/min X 3333 
Patients were also divided according to the serum LDH levels into  
1. <600 IU/l 
2. 600–800 IU/l 
3. >800 IU/l 
v All women were followed until delivery and early postpartum 
period.  
v S.LDH values were correlated with the severity of the disease in 
terms of maternal complications like HELLP, Eclampsia, 
Abruptio Placenta, maternal death & fetal complications like 
IUGR, still birth, late IUD.  
v Factors taken for analysis were age, parity and gestational age 
in weeks and mode of Delivery.  
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v Definitions used for defining pre-eclampsia were according to 
International Society for the Study of Hypertension in 
Pregnancy (ISSHP). Classification into mild and severe pre-
eclampsia were based on NHBPEP classification.  
v HELLP syndrome was diagnosed based on Mississippi 
criteria.  
v IUGR 
Fetuses with a birth weight less than 10th percentile of those born at 
the same gestational age or two standard deviation below the population 
mean were considered IUGR. (5). 
v IUD 
Death prior to complete expulsion or extractions from its mother of 
a product of human conception after 28 weeks of gestations is considered 
as late intra uterine fetal death. (31). 
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Fig-17. Materials Used in LDH estimation 
(a). Centrifuge 
 
(b). Pipette 
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(c). Reagent 
 
(d). Instruction Sheet 
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OBSERVATION AND RESULTS 
A total of 173 antenatal women were recruited from Outpatient 
department/ Labour Ward at Chengalpattu Medical College & Hospital 
from  November 2013 ~ August  2014 
All patients were of gestational age 28 weeks and above. Patients 
were selected irrespective of the age and parity and they were divided 
into three groups based on NHBPEP classification as 50 normotensives, 
50 mild pre-eclamptics, 50 severe pre-eclamptics & 23 eclamptics. 
Patients were also divided into three groups based on their S. LDH (less 
than 600, 600 to 800, and more than 800 IU/l). 
Influences of age and parity on S. LDH were analyzed using 
appropriate statistical test. 
correlation between S. LDH and maternal and fetal complications 
were studied using appropriate statistical test. 
One-way analysis of variance (ANOVA) and the chi-square test 
were used to compare the results. Differences were considered significant 
when p<0.05. 
The following observation were made and results derived from this 
study. 
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Table 5- Distribution of Cases based on Age 
Age Group 
Controls Mild  pre-eclampsia 
Severe pre-
eclampsia Eclampsia 
n % n % n % n % 
19 & Below 1 2 1 2 1 2 0 0 
20 to 23 26 52 20 40 27 54 14 60.87 
24 to 28 17 34 24 48 16 32 6 26.09 
29 & Above 6 12 5 10 6 12 3 13.04 
Total 50 100 50 100 50 100 23 100 
 
Distribution of age in between groups were analysed using 
ANOVA test. The mean age of patients in Controls, mild pre-eclampsia, 
severe pre-eclampsia &  eclampsia  are 23.64, 24.46, 24.08 & 23.95 and 
their standard deviations are 3.08, 3.69, 3.41 & 3.92 respectively. F Value 
is 0.47; P Value is 0.70. 
Inference:  
There is no statistically significant difference in the distribution 
of age between groups. 
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Table 6- Correlation between S.LDH & Age 
S.LDH No Mean Age ± Std. Deviation 
<600 121 23.95 ± 3.48 
600 to 800 20 24.10 ± 2.75 
> 800 32 24.34 ± 3.82 
 
Out of the total 173 women 121 patients had S. LDH less than 600, 
20 had values between 600 and 800 and 32 had values more than 800. 
The Mean age of the patients with S.LDH less than 600, 600 to 800 
and more than 800 are 23.95, 24.10 and 24.34 and their standard 
deviations are 3.48, 2.75 and 3.82 respectively. 
2-Tailed test was applied and P value of 0.21 was obtained 
Inference: 
There is no statistically significant correlation between age and 
S.LDH. 
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Table 7- Distributions of Cases Based on Parity 
Parity Total 
Controls Mild  pre-eclampsia 
Severe pre-
eclampsia Eclampsia 
n % n % n % n % 
G1 104 25 50 29 58 32 64 18 78 
G2 49 21 42 14 28 12 24 2 9 
G3 15 3 6 6 12 3 6 3 13 
G4 & 
Above 5 1 2 1 2 3 6 0 0 
Total 173 50 100 50 100 50 100 23 100 
 
The study included 104 primigravida and 69 women with gravida 2 
and above irrespective of the outcome of previous pregnancies. 
Distribution of parity in between groups were analysed using chisquare  
test, chisquare value is 13.62 & P value is 0.14. 
Inference:  
There is no statistically significant difference in the distribution 
of parity between groups.  
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Table 8 - Correlation between S. LDH & Parity 
S.LDH 
Parity 
G1 G2 G3 G4 & Above 
n % n % n % n % 
<600 71 58.68 40 33.06 8 6.61 2 1.65 
600 to 800 11 55.00 5 25.00 4 20.00 0 0.00 
>800 22 68.75 4 12.50 3 9.38 3 9.38 
 
Out of the 121 women with S. LDH less than 600, 58.68% women 
were primigravida and 41.32 % were gravida 2 and above 
Out of the 20 women with LDH values between 600 and 800, 
55.00% were primigravida and 45.00% were gravida 2 and above 
Out of the 32 women with LDH more than 800, 68.75% were 
primigravida and 31.25% were gravida 2 and above 
Influence of parity on S.LDH was studied using TUKEY HSD test. 
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Table 8.1- Influence of Parity on S. LDH 
Parity Parity Mean Difference of LDH 
Std. 
Error Sig. 
G1 
G2 170.358 85.325 0.193 
G3 -115.446 136.006 0.831 
G4 & Above -407.646 225.454 0.273 
G2 
G1 -170.358 85.325 0.193 
G3 -285.804 145.309 0.205 
G4 & Above -578.004 231.186 0.063 
G3 
G1 115.446 136.006 0.831 
G2 285.804 145.309 0.205 
G4 & Above -292.2 254.291 0.66 
G4 & 
Above 
G1 407.646 225.454 0.273 
G2 578.004 231.186 0.063 
G3 292.2 254.291 0.66 
 
Inference: 
Parity is not statistically related to the changes in S.LDH 
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Table 9- Comparison of S. LDH in Cases & Controls 
S.LDH Controls Mild  pre-eclampsia 
Severe pre-
eclampsia Eclampsia 
Mean ± Std 
Deviation 
275.4  ±  
108.36 
381.42  ±  
178.93 
660.84  ±  
456.08 
1360.43  ±  
677.13 
Max 494 793 1600 3200 
Min 101 109 104 340 
Range 393 684 1496 2860 
 
S.LDH values between groups were analysed using ANOVA test. 
The mean S.LDH value of controls, mild pre-eclampsia, severe 
pre-eclampsia and eclampsia are 275.4, 381.42, 660.84 & 1360.43 and 
their standard deviations are 108.36, 178.93, 456.08 & 677.13 
respectively. 
TUKEY HSD test was applied to study the difference in S. LDH 
between groups  
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Table 9.1- Difference in S. LDH between Groups 
Group Group Mean Difference of S. LDH 
Std. 
Error Sig. 
Mild pre-
eclampsia Controls 106.02 72.853 0.47 
Severe pre-
eclampsia Controls 385.440 72.853 0.00 
Severe pre-
eclampsia 
Mild pre-
eclampsia 279.420 72.853 0.00 
Eclampsia Controls 1085.035 91.776 0.00 
Eclampsia Mild pre-eclampsia 979.015 91.776 0.00 
Eclampsia Severe pre-eclampsia 699.595 91.776 0.00 
 
Inference:  
There is no statistically significant difference in the S. LDH 
levels between controls and mild pre-eclampsia with P value of 0.47 
but  as  the  severity  of  the  disease  goes  up  there  is  a  significant  
increase in S.LDH as shown in the above table.( p iess than 0.00 ) 
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Table 10- Correlation between S. LDH & SBP 
SBP (mmHg) 
S.LDH 
Below 600 600 to 800 Above 800 Total 
90 to 139 50(41.32%) 0 (0.00%) 0 (0.00%) 50 
140 to 159 47 (38.84%) 12 (60.00%) 7 (21.87%) 66 
160 & Above 24 (19.83%) 8 (40.00%) 25 (78.12%) 57 
Total 121 20 32 173 
 
Out of total 121 patients with LDH levels <600 IU/l, 50 (41.32%) 
cases had normal SBP, 47 (38.84%) had SBP in the range of 140 to 
159 mm of Hg and 24 (19.83%) had SBP 160 and above. Out of 20 
patients with LDH levels between 600 and 800 IU/l, none had normal 
SBP, 12 (60%) had SBP in the range of 140 to 159 mm of Hg and 8 
(40%) had SBP 160 and above. In the remaining 32 patients with LDH 
levels above 800 IU/l, none had normal SBP, 7 (21.87%) had SBP in the 
range of 140 to 159 mm of Hg and 25 (78.12%) had SBP 160 and above.  
Chi-square test was applied to study the correlation between SBP 
and S.LDH.  Correlation coefficient is 0.369, chi-square value is 52.67 
and P Value is 0.00;  
Inference: There was a significant rise in S.LDH with Systolic Blood 
Pressure.  
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Table 11- Correlation between S. LDH & DBP 
DBP (mmHg) 
S.LDH 
Below 600 600 to 800 Above 800 Total 
60 to 89 56 (46.28%) 1 (5.00%) 0 (0.00%) 57 
90 to 109 51 (42.14%) 10 (55.00%) 5 (15.6%) 66 
110 & Above 14 (11.57%) 9 (45.00%) 27 (84.37%) 50 
Total 121 20 32 173 
 
Out of total 121 patients with LDH levels <600 IU/l, 56(46.28%) 
had normal DBP, 51 (42.14%) had DBP in the range of 90 to 109 mm of 
Hg and 14 (11.57%) had DBP 110 and above. Out of 20 patients with 
LDH levels between 600 and 800 IU/l, one (5%) had normal DBP, 10 
(55%) had DBP in the range of 90 to 109 mm of Hg and 9 (45%) had 
DBP 110 and above. In the remaining 32 patients with LDH levels above 
800 IU/l, none had normal DBP, 5 (15.6%) had DBP in the range of 90 
to109 mm of Hg and 27 (84.37%) had DBP 110 and above.  
Chi-square test was applied to study the correlation between DBP 
and S.LDH.  Correlation coefficient is 0.393, chi-square value is 75.75 
and P Value is 0.00;  
Inference: There was a significant rise in S.LDH with Diastolic 
Blood Pressure.   
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Table 12- Correlation between S. LDH & Severity of Proteinuria 
U/A 
S. LDH 
Below 600 600 to 800 Above 800 Total 
1+ (0.3 g/L) 3 0 0 3 
2+ (1.0 g/L) 56 10 3 69 
3+ (3.0 g/L) 14 6 11 31 
4+ (10.0 g/L) 1 4 18 23 
 
Out of the total 173 patients 41 did not have proteinuria, 6 had 
proteinuria in the range of 0.1 g/L and 3 had proteinuria in the range of 
0.3 g/L, whose LDH levels were <600.  
69 patients had proteinuria in the range of 1.0g/L, out of which 56 
(81.16%) had LDH levels <600, 10 (14.49%) had LDH levels between 
600 and 800 and 3 (4.35%) had LDH levels more than 800.  
31 patients  had  proteinuria in the range of 3.0g/L, out of which 14 
(45.16%) had LDH levels <600, 6 (19.35%) had LDH levels between 600 
and 800 and 11(35.48%) had LDH levels more than 800.  
23 patients  had proteinuria in the range of 10.0g/L, out of which 1 
(4.35%) had LDH levels <600, 4 (17.39%)  had LDH levels between 600 
and 800 and 18 (78.26%) had LDH levels more than 800. 
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Chi-square test was applied to study the correlation between S. 
LDH and severity of proteinuria.  Correlation coefficient is 0.567, chi-
square value is 58.35 & P Value is 0.00;  
Inference: There was a significant rise in S.LDH with 
increasing proteinuria.  
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Table 13-Correlation between S. LDH & Abruptio Placenta 
S.LDH Below 600 
600 to 
800 
800 & 
Above 
Correlation 
Coefficient 
Sig. (2-
tailed) 
Abruptio 
Placenta 10 9 13 0.271 0.00 
 
Out of the total 173 women 32 had abruptio placenta out of which 
14 women had mild pre-eclampsia.  Of these women 10 women had LDH 
values less than 600, 4 had LDH values between 600 and 800 and none 
had LDH values above 800. 18 had severe pre-eclampsia out of which 
none had LDH values less than 600, 5 had LDH values between 600 and 
800 and 13 others had LDH more than 800.  
Chi-square test was applied to study the correlation between S. 
LDH and abruptio placenta. 
  Correlation coefficient is 0.271. 
chi-square value is 28.12.  
P Value is 0.00. 
Inference: There was a significant rise in S.LDH in patients with 
abruptio placenta  
 
93 
 
 
 
 
  
94 
 
Table 14- Correlation between S. LDH & Maternal Mortality 
S.LDH Below 600 
600 to 
800 
800 & 
Above 
Correlation 
Coefficient 
Sig. (2-
tailed) 
Maternal 
Mortality 0 0 3 0.160 0.01 
 
Totally 3 maternal deaths were reported, 1 from severe pre-
eclampsia  due  to  HELLP  with  DIC  and  2  from  Eclampsia,  both  due  to  
pulmonary edema. No maternal deaths occurred in the normotensives and 
mild pre-eclampsia groups. All 3 women had very high LDH levels with 
a mean value of 1943.33 and standard deviation of 499.78 compared to 
the mean value of 275.4 and standard deviation of 108.36 in 
normotensive women. 
Chi-square test was applied to study the correlation between S. 
LDH and maternal mortality.  
Correlation coefficient is 0.160. Chi-square value is 13.45 and P 
Value is 0.01.  
Inference: There was a significant rise in S.LDH in patients 
with maternl mortality  
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Table 15- Correlation between S. LDH and Operative Delivery 
Mode of Delivery 
S. LDH 
<600 600 to 800 >800 
n % n % n % 
LSCS 60 49.59 18 90.00 26 81.25 
LN 61 50.41 1 5.00 5 15.63 
Asst. Breech 0 0.00 1 5.00 1 3.13 
 
Out of the total 173 patients 104 women delivered by LSCS, 67 by 
normal vaginal delivery and 2 by assisted breech delivery and none by 
instrumental delivery.   Among the women who delivered by cesarean 60 
(57.69%) had S.LDH less than 600, 18 (17.30%) had S. LDH between 
600 and 800 and 26(25.00%) had S.LDH above 800.  
Among the women who delivered vaginally 61 (91.04%) had 
S.LDH less than 600, 1 (1.49%) had S. LDH between 600 and 800 and 5 
(7.46%) had S.LDH above 800. Only 2 women delivered by assisted 
breech delivery one with S. LDH between 600 and 800 and another with 
S.LDH above 800. 
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Mode of Delivery 
S. LDH 
<600 >600 
n % n % 
LSCS 60 49.59 44 84.62 
LN 61 50.41 6 11.54 
Asst. Breech 0 0.00 2 3.85 
 
The incidence of operative delivery significantly increased with S. 
LDH levels upto 800 and then it declined probably because of the early 
onset of spontaneous labour in eclamptic women. When the parameters 
were taken as S. LDH levels less than 600 and more than 600 there was 
as significant increase in the incidence of operative delivery. 
Correlation coefficient value is 0.207, P value is 0.00 
Inference:  
There was a significant rise in S.LDH in patients with operative 
delivery Correlation between S.LDH and operative delivery explains 
the severity of the disease with increased LDH and the need for 
immediate delivery in them. 
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Table 16 - Correlation between S. LDH & Mean GA 
S.LDH 
Below 
600 
600 to 
800 
Above 
800 
Correlation 
Coefficient 
Sig. (2-
tailed) 
GA (weeks) Mean  
± Std. Deviation 
38.198 
± 2.16 
37.05 
± 2.89 
34.46 
± 3.45 
-0.276 0.00 
   
The mean gestational age at the time of delivery in patients with S. 
LDH less than 600, 600 to 800 and more than 800 are 38.19, 37.05 & 
34.46 and their standard deviations are 2.16, 2.89 & 3.45 respectively. 
Correlation coefficient is -0.276, P value is 0.00 
Inference:  
There is reduction in the mean GA with higher level of LDH 
(P = 0.00). This fact could be explained by the increased preterm 
deliveries associated with pre-eclampsia. 
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Table 17- Correlation between S. LDH & Mean Baby Weight 
S.LDH 
Below 
600 
600 to 
800 
Above 
800 
Correlation 
Coefficient 
Sig. (2-
tailed) 
Mean Baby Weight 
(kg) ± Std. Deviation 
2.76± 
0.54 
2.377
± 0.59 
1.83 ± 
0.59 
-0.274 0.00 
 
The mean baby weight in patients with S. LDH less than 600, 600 
to 800 and more than 800 are 2.76, 2.37 & 1.83 kg and their standard 
deviations are 0.54, 0.59 & 0.59 kg respectively. 
Correlation coefficient is -0.274, P value is 0.00 
Inference:  
This proves that there is reduction in the average weight of 
babies with higher level of LDH (P = 0.00) with a perfect negative 
correlation of 0.274 probably because of the higher incidence of 
growth restriction and preterm deliveries among preeclamptic 
women with higher S. LDH levels. 
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Table 18- Correlation between S. LDH & Fetal Growth Restrictions 
S.LDH Below 600 600 to 800 
800 & 
Above 
Correlation 
Coefficient 
Sig. (2-
tailed) 
IUGR 0 3 4 0.205 0.00 
 
Out of the total 173 women 7 had growth restricted babies out of 
which 4 women had severe pre-eclampsia, 3 0f the 4 women had LDH 
values between 600 and 800 and 1 had LDH values above 800. 3 out of 
the 7 women with growth restricted babies had Eclampsia and all three 
had S.LDH more than 800. 
Correlation between S.LDH and intra uterine growth restriction is 
studied using chi-square test. 
Correlation coefficient is 0.205, Chi-square value is 17.17,  
P Value is 0.00; 
Inference:  
There was a significant rise in S.LDH with incidence of Intra 
Uterine Growth Restriction with a positive correlation of 0.205. 
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Table 19- Correlation between S. LDH & Late Intra Uterine  
Fetal Death 
S.LDH Below 600 
600 to 
800 
800 & 
Above 
Correlation 
Coefficient 
Sig. (2-
tailed) 
LATE 
IUD 5 5 10 0.265 0.00 
 
Out of the total 173 women 20 had late intra uterine fetal death out 
of which 9 women had mild pre-eclampsia, 5 0f the 9 women had LDH 
values less than 600, 4 had LDH values between 600 and 800 and none 
had LDH values above 800. 10 out of the 20 women with late intra 
uterine fetal death had severe pre-eclampsia, only 1 had LDH values 
between 600 and 800 and all others had S.LDH more than 800. Only 1 
woman in the Eclampsia group had late intra uterine fetal death with 
S.LDH more than 800.  
Correlation between S.LDH and IUD is studied using chi-square 
test.  
Correlation coefficient is 0.265, Chi-square value is 22.19.  
P Value is 0.00. 
Inference: There was a significant rise in S.LDH with IUD 
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DISCUSSION 
This study is conducted in the Department of Obstetrics and 
Gynecology, Chengalpattu Medical College. 
A total of 173 antenatal women were recruited from Outpatient 
department/ Labour Ward at Chengalpattu Medical College & Hospital 
from  November 2013 ~ August  2014 
All patients were of gestational age 28 weeks and above. Patients 
were selected based on the inclusion and exclusion criteria  irrespective 
of the age and parity and they were divided into three groups based on 
NHBPEP classification as 50 normotensives, 50 mild pre-eclamptics, 50 
severe pre-eclamptics & 23 eclamptics. Patients were also divided into 
three groups based on their S. LDH (less than 600, 600 to 800, and more 
than 800 IU/l). 
All the diagnostic components and the possible maternal and fetal 
complications of pre-eclampsia were correlated with their S.LDH levels. 
This  study  is  similar  to  the  study  done  by  S.P Jaiswar, Amrit 
Gupta and Mohan Shaili at CSSM, Lucknow. 
The distribution of age & mean age between groups were almost 
similar. No significant difference was observed in terms of age and 
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parity between groups and moreover they did not influence S.LDH in 
contrast to Qublan et al and Jaiswar et al. Qublan et al stated that the 
mean age of patients in preeclampsia was significantly less compared to 
the normotensives and majority were young primigravida in the affected 
population. 
S. LDH levels consistently increased with increasing systolic & 
diastolic blood pressure, more so with diastolic blood pressure with a P 
value of <0.001 similar to Jaiswar & Amrit et al. 
Jaiswar & Amrit et al in their study observed a mean S. LDH of 
278.33 ± 119.25 in normotensives,400.45 ± 14.21 in mild pre-
eclampsia,646.95 ± 49.64 in severe pre-eclampsia,1648.10 ± 1992.29 in 
eclampsia with a P value <0.001. Similar results were observed in this 
study with mean S. LDH of 275.4 ± 108.38 in normotensives, 381.42 ± 
178.93 in mild pre-eclampsia, 660.84 ± 456.08 in severe pre-eclampsia 
and 1648 ± 677.13 in eclampsia with a P value of <0.001. 
Most of the women with severe preeclampsia & eclampsia had 
severe proteinuria and S. LDH significantly increased with the severity of 
proteinuria (P<0.00). Results were comparable to Qublan et al who 
showed a significant increase in S. LDH with severity of proteinuria( P 
value of <0.05). 
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In the study done by S.P.Jaiswar et al, only 2 cases had abruptio 
placenta but the incidence was tremendously high with 32 cases in this 
group. Significantly high LDH values were observed than controls P 
(0.00) among them. 
Only 1 case of HELLP syndrome was present in the study. 
Totally 3 maternal death occurred in the study population and all of 
them had very high LDH levels. 2 deaths were due to pulmonary edema 
and 1 due to DIC. All the three patients needed ventilatory support. 
Other maternal complications like CVA, Postpartum hemorrhage, 
renal failure were not present in the study population. Still births were not 
present in the study population probably because of the close fetal 
surveillance, early decision and increased operative delivery among pre-
eclamptic women. 
The incidence of operative delivery moderately elevated with 
increased LDH levels and this explains the severity of the disease with 
increased LDH and the need for immediate delivery in them. 
The mean gestational age at the time of delivery in patients with 
S. LDH less than 600, 600 to 800 and more than 800 are 38.19, 37.05 & 
34.46 and their standard deviations are 2.16, 2.89 & 3.45 respectively. 
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The mean baby weight in patients with S. LDH less than 600, 600 
to 800 and more than 800 are 2.76, 2.37 & 1.83 kg and their standard 
deviations are 0.54, 0.59 & 0.59 kg respectively 
Mean GA and mean baby weight had negative correlation with S. 
LDH levels with P value < 0.00 similar to Jaiswar et al whose mean GA 
at the time of delivery was significantly less in patients with increasing 
LDH levels (P  value  = 0.025). This  fact  could  be  explained  by  the  
increased preterm deliveries and the need for early termination of 
pregnancy to improve the maternal outcome in view of severity of 
disease.  
Complications like growth restriction & late intrauterine fetal 
demise are well known complication of pre-eclampsia. He S , Bremme 
K, Kallner et al studied the S. LDH levels in pre-eclamptic women with 
small for gestational age infants and found a significant correlation 
between both. Incidence of IUGR and IUD were significantly higher in 
pre-eclamptic women and their S. LDH levels compared to the controls 
were abnormally high (P value < 0.00) similar to He. S et al. 
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SUMMARY 
This was a comparative observational study done on 173 patients 
attending Outpatient department/ Labour Ward at Chengalpattu Medical 
College & Hospital, Chengalpattu from  November 2013 ~ August  2014 
 All patients were of gestational age 28 weeks and above. Patients were 
selected irrespective of the age and parity and they were divided into 
three groups based on NHBPEP classification as 50 normotensives, 50 
mild pre-eclamptics, 50 severe pre-eclamptics & 23 eclamptics. Patients 
were also divided into three groups based on their S. LDH (less than 600, 
600 to 800, and more than 800 IU/l). All the diagnostic components and 
the possible maternal and fetal complications of pre-eclampsia were 
correlated with their S.LDH levels. 
The study was done in search of a valuable marker for 
preeclampsia and Eclampsia which would reflect the severity of the 
disease and would predict the maternal and fetal outcome. Such markers 
can help in decision making and can influence the current management 
protocols in order to achieve a better maternal and perinatal outcome.  
Lactate dehydrogenase has been suggested by various authors as a 
promising marker and the inferences made out of this study are as 
follows. 
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1. Age  &  Parity  did  not  have  any  relation  with  S.  LDH  levels  of  
P(0.21) 
2. Systolic & Diastolic blood pressure had significant correlation with 
S. LDH levels with a P value of 0.00 
3. S. LDH levels did not vary much between normotensives and mid 
preeclampsia (P =0.47) but significant increase was observed 
between normotenisves, severe pre-eclampsia & eclampsia 
(p<0.00) 
4. Proteinuria by itself is a marker of severity of the disease and 
correlating LDH values P (0.00) proves  S.  LDH  to  be  a  similar  
marker with high significance and hence the need for management 
strategies based on S. LDH. 
Among the 121cases with normal LDH levels (<600 IU/L),  
109 cases (90.08%) had uneventful maternal outcome. 
12 cases (9.91%) had maternal complications which include  
10 cases (8.26%) with abruptio placenta, 
2 cases (1.65%) with Eclampsia. 
No IUGR cases were observed. 
5 cases (4.14%) of late fetal deaths were reported. 
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Among the 20 cases with LDH levels between 600-800 IU/L, 
7 cases (35%) had uneventful maternal outcome. 
13 cases (65%) had maternal complications which include  
9 cases (45%) with abruptio placenta,  
4 cases (20%) with Eclampsia. 
3 cases (15%) had IUGR. 
5 cases (25%) had late fetal death. 
Among the 32 cases with LDH levels more than 800 IU/L, 
Only one case (3.12%) had uneventful maternal outcome. 
31 cases (96.88%) had maternal complication which include  
13 cases (40.62%) with abruptio placenta, 
1 case (3.12%) with HELLP & DIC leading to maternal 
death, 
17 cases (53.12%) with Eclampsia including 2 maternal 
deaths due to pulmonary edema. 
4 cases (12.5%) had IUGR.  
10 cases (31.25%) had late fetal death..  
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Overall incidence of maternal complications (Abruption, 
Pulmonary Edema, DIC, HELLP) were 50% with increased LDH values 
(>600 IU/L) when compared to 8.26% with normal LDH values (<600 
IU/L). Significantly high maternal morbidity and mortality were 
observed with high LDH levels (P= 0.00). 
There was an overall incidence of fetal complication ( IUGR + 
IUD ) of 42.3 % with increased LDH values (>600 IU/L) when 
compared to 4.13 % with normal LDH values (<600 IU/L). Significantly 
high fetal complications were observed with high LDH levels (P=0.00). 
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CONCLUSION 
After analyzing the data and comparing the results following 
conclusion have been drawn from the study. 
S. LDH values were significantly high in pre-eclamptic patients 
depending on the severity of the disease indicating the increased cellular 
turnover in them. 
S. LDH levels had a good correlation with all the diagnostic 
components of preeclampsia like SBP, DBP & Proteinuria, similarly with 
maternal and fetal morbidity and mortality 
Hence diagnostic and management strategies may be considered 
based on S.LDH levels and further studies on a larger sample can be done 
to substantiate our observations on the utility of this parameter as a 
diagnostic and prognostic component of preeclampsia. Development of 
new management strategies based on S. LDH levels may help in 
appropriate decision making thereby avoiding unwanted maternal & fetal 
deaths. 
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ANNEXURE-II 
COPY OF INFORMED CONSENT 
ஆராvசி ஒ~©த கத 
ஆராvசி தைல~© : 
ெபயƫ    :    ேததி : 
வய¢    : 
ெவள ேநாயாள எz : 
பா    :  
ஆராvசி ேசƫtைக எz : 
 
            இ|த ஆராvசிய} வவரuக¶ அத} 
ேநாtகuக¶ «¸ைமயாக எனt ெதளவாக 
வளtக~பyட¢.  
எனt வளtக~பyட வஷயuகைள நா} ©Ƭ|¢ 
ெகாz நா} என¢ சமத{ைத{ ெதƬவtகிேற}. 
            இ|த ஆராvசிய பறƬ} நிƫ~ப|தமி}றி எ} 
ெசா|த வ¯~ப{தி} ேபƬ தா} பu ெப²கிேற} 
ம² நா} இ|த ஆராvசியலி¯|¢ எ|ேநர« 
ப}வாuகலா எ}பைத­ அதனா எ|த பாதி~© 
ஏபடா¢ எ}பைத­ நா} ©Ƭ|¢ெகாzேட}. 
            இ|த ஆராvசிய} வவரuகைளt ெகாzட 
தகவ தாைள~ ெப²tெகாzேட}.  
நா} எ}§ைடய யநிைனºட} ம² «¸ 
த|திர{¢ட} இ|த ம¯{¢வ ஆராvசிய 
எ}ைன­ ேசƫ{¢tெகாள சமதிtகிேற}. 
 
 
 
ேநாயாள/ உட} இ¯~பவƫ ைகெயா~ப 
 
  
  
ANNEXURE-III 
 
COPY OF PATIENTS INFORMATION SHEET 
 
ஆராvசி  தகவ தா 
 
 
ெசuகபy அர ெபா¢  ம¯{¢வமைணய 
மக~ேப²  நல~பƬவ கƫ~ப கால{தி 
ெபzக¶t ஏப இர{த அ¸{த ம² 
அத} ப}வைளºக பறிய ஆராvசி 
நைடெப² வ¯கி}ற¢. 
நuக¶  இ|த  ஆராvசிய  பuேகக  
நாuக வ¯©கிேறா. இதனா உuக¶t எ|த 
பாதி~© ஏபடா¢   எ}பைத   ெதƬவ{¢ 
ெகாகிேறா. 
«ºகைள அல¢ க¯{¢கைள 
ெவளயேபா¢ அல¢ ஆராvசிய}ேபா¢ 
உuக ெபயைரேயா அல¢ 
அைடயாளuகைளேயா ெவளயடமாyேடா 
எ}பைத ெதƬவ{¢ெகாகிேறா. 
இ|த  ஆராvசிய  பuேகப¢  தuக¶ைடய 
வ¯~ப{தி}ேபƬ தா} இ¯tகிற¢. ேம´ 
நuக எ|ேநர« இ|த ஆராvசியலி¯|¢ 
ப}வாuகலா எ}பைத ெதƬவ{¢ெகாகிேறா. 
இ|த சிற~© பƬேசாதைனகள} «ºகைள 
ஆராvசிய}ேபா¢ அல¢ ஆராvசிய} 
«வ}ேபா¢ தuக¶t அறிவ~ேபா 
எ}பைத­ ெதƬவ{¢ெகாகிேறா. 
 
  
ANNEXURE – IV 
 
PROFORMA 
 
Name:      Date of Delivery: 
Age/ Sex:      Date of Admission: 
IP.  No:      Date of Discharge: 
Socio-Economic Status: 
Obstetric Formula: 
LMP:    EDD:    WEEKS OF GESTATION: 
Chief Complaints: 
History of Present Illness: 
Obstetric History: 
Past: 
Present: 
1st TRIMESTER 
2nd TRIMESTER 
3rd TRIMESTER 
Menstrual h/o: Menarche  , Cycles  , Flow   
Marital h/o:  years, Consanguinity:  
Previous Medical Illness: 
v Hypertension v Diabetes v Autoimmune Disease 
v Dilatation & Curettage v Tuberculosis v Seizure Disorder 
v Bleeding Disorders v Bronchial Asthma v Thyroid Disorder 
v Heart Disease v Immunosupression v Renal/ Liver Disease 
v Others   
  
Family H/O: 
General Examination: 
Consciousness:     Height: 
Pallor:      Weight: 
Icterus:      BMI: 
Pedal Edema:     Temp: 
CVS:         Pr:       / min  
RS:        Bp:      /      mmHg 
Per Abdomen: 
Inspection: 
Palpation: 
Ausculation: 
Per Speculum: 
Per Vaginum: 
Diagnosis: 
Investigations: 
v Serum LDH 
v Blood Grouping & Typing 
v Complete Hemogram 
v Urine Routine 
v Bleeding Time 
v Clotting Time 
v Renal Function Test 
  
v Liver Function Test 
v HIV I & II 
v Fundus Evaluation 
v 24hrs Urine Protein 
Obstetric Sonogram: 
Singleton/ Multiple/ Viability/ Gestational Age/ Placental Position/ Retro 
Placental Clots/ Presentation/ Liquor/ IUGR/ IUD 
Mode of Delivery:  
Normal Vaginal Delivery/ Assisted/ Forceps/ LSCS 
v Intra-op Findings: 
v RP Clots:      gms 
v Postpartum Haemorrhage   Yes/ No ml 
Perinatal Complications: 
v Eclampsia      Yes/No 
v ICU Care        Yes/ No 
v Blood/ Blood Products                             Yes/No                          
v DIC/Shock     Yes/No 
v Pulmonary Edema                               Yes/No 
v Ventilator Care                                    Yes/No 
v HELLP                                                Yes/No   
v Renal Failure                                       Yes/No 
v Abruptio Placenta                                Yes/No 
v CVA/ Intracranial Hemorrhage           Yes/No 
  
v Hysterectomy     Yes/ No 
v Sepsis      Yes/ No 
v Maternal Mortality    Yes/ No 
v Cortical blindness                                Yes/No 
v Adult respiratory distress syndrome    Yes/No 
v Hepatic rupture                                    Yes/No        
Fetal/ Neonatal Outcome: 
v IUGR 
v Live/ Stillbirth/ Neonatal Death 
v Term/ Preterm (BIRTH WT:     Kgs) 
v NICU Care 
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1 Thamaraikanni 20 46090 Primi Eclampsia 37 768 EM. LSCS   1     2.54     180 120 3+ 
2 Sarasu 20 47095 G3P1L1A1 Eclampsia 39 340 EM. LSCS   1     3.5     176 110 3+ 
3 Lalitha 24 48065 Primi Eclampsia 38 720 EM. LSCS   1     2.8     150 100 2+ 
4 Selvakumari 30 48396 Primi Eclampsia 36 745 EM. LSCS   1     2.7     160 94 4+ 
5 Vidhya 23 46376 G2A1 Severe Pre-eclampsia 30 240 EM. LSCS         1.2     140 120 3+ 
6 Rajeshwari 30 46798 G2P1L1 Severe Pre-eclampsia 39 190 EM.Rpt LSCS         2.8     160 82 2+ 
7 Valarmathi 27 48356 Primi Severe Pre-eclampsia 36 204 EM. LSCS         2.2     150 94 3+ 
8 Shakila 20 49096 Primi Severe Pre-eclampsia 41 203 EM. LSCS         2.75     160 126 3+ 
9 Kaliyammal 27 46846 G5P2L1A1 Severe Pre-eclampsia 36 1563 EM. LSCS     1   2.3     140 112 4+ 
10 Kala 34 46821 G2P1L1 Mild Pre-eclampsia 38 450 EM. LSCS     1   3     150 90 1+ 
11 Vidhya 27 48350 Primi Severe Pre-eclampsia 28 1420 EM. LSCS     1   1   1 160 110 4+ 
12 Sumathi 36 46426 Primi Mild Pre-eclampsia 37 562 EM. LSCS         2.3     150 90 1+ 
13 Kotteswari 21 46089 Primi Mild Pre-eclampsia 40 230 EM. LSCS         3.25     146 90 1+ 
14 Arul Mozhi 20 49186 G2P1L1 Controls 39 110 LN         2.75     120 74 NIL 
15 Jayanthi Rani 19 49128 Primi Controls 38 220 LN         2.75     112 78 1+ 
16 Sathya 24 49100 G2P1L1 Controls 39 300 LN         2.75     110 82 Trace 
17 Dhanalakshmi 28 49206 G2P1L1 Controls 38 432 LN         2.2     100 70 NIL 
18 Pandiyammal 23 49676 Primi Eclampsia 36 1983 EM. LSCS   1     1.8 1   190 136 3+ 
19 Vasanthi 20 49723 G3A2 Eclampsia 28 1831 EM. LSCS   1     1   1 172 120 4+ 
20 Susheela 22 50944 Primi Eclampsia 32 1930 EM. LSCS   1     1.5     150 100 2+ 
21 Gomathi 21 57583 Primi Eclampsia 34 1030 EM. LSCS   1     1.9     160 110 4+ 
22 Kalpana 24 51625 G3P2L1 Eclampsia 36 1893 EM. LSCS   1     1.8 1   184 122 4+ 
23 Kanniga 22 50221 G2A1 Severe Pre-eclampsia 40 104 EM. LSCS         3.25     160 100 1+ 
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24 Chandra 30 50572 Primi Severe Pre-eclampsia 38 230 EM. LSCS         2.6     160 90 2+ 
25 Kavitha 26 57362 Primi Severe Pre-eclampsia 39 405 EM. LSCS         3.4     150 80 3+ 
26 Poongodi 23 57575 Primi Severe Pre-eclampsia 37 398 EM. LSCS         2.5     160 80 2+ 
27 Selvi 31 49696 G2P1L1 Severe Pre-eclampsia 38 1009 EM. LSCS     1   2 1 1 160 124 3+ 
28 Kannagi 24 49731 G2P1L1 Mild Pre-eclampsia 32 294 EM. LSCS     1   1.6     144 92 1+ 
29 Rajeshwari 33 57539 G4P1L1A2 Severe Pre-eclampsia 41 1203 EM.Rpt LSCS     1   3     164 90 2+ 
30 Kamarunisha 23 57680 Primi Severe Pre-eclampsia 40 1302 EM. LSCS     1   3.25     150 112 4+ 
31 Poornima 21 49127 Primi Mild Pre-eclampsia 38 230 LN     1   3.2     140 92 1+ 
32 Murugavalli 23 49404 Primi Mild Pre-eclampsia 40 532 EM. LSCS         3.6     144 90 Trace 
33 Shantha 27 50033 Primi Mild Pre-eclampsia 40 435 EM. LSCS         3.25     150 80 Trace 
34 Suganthi 21 49101 Primi Controls 40 456 LN         3.5     110 70 NIL 
35 Mohana 29 49134 Primi Controls 40 210 LN         2.4     122 80 Trace 
36 Lakshmi 22 49113 Primi Controls 40 222 LN         3     120 70 NIL 
37 Bargath 23 49142 G2P1L1 Controls 40 340 LN         3     110 60 NIL 
38 Revathi 20 2609 Primi Eclampsia 38 1934 EM. LSCS   1     1.8 1   220 140 3+ 
39 Arul Jyothi 21 3400 Primi Eclampsia 34 1732 Ass Breech   1     1.7     140 96 2+ 
40 Nirmala 26 1457 Primi Severe Pre-eclampsia 37 1600 LN 1     1 2.35     160 130 4+ 
41 Nithya 19 3113 Primi Severe Pre-eclampsia 30 1048 LN     1   1.1   1 170 124 4+ 
42 Jeyabarathi 22 1128 G2A1 Mild Pre-eclampsia 39 355 LN     1   3.3     150 90 1+ 
43 Jerina 22 427 G2P1L1 Severe Pre-eclampsia 40 420 EM. LSCS         2.5     160 112 3+ 
44 Deivanayaki 21 1998 Primi Severe Pre-eclampsia 40 689 EM. LSCS         2.1 1   170 110 3+ 
45 Nandhini 20 2120 Primi Severe Pre-eclampsia 39 643 EM. LSCS         1.75 1   160 120 4+ 
46 Jayasree 30 369 G2P1L1 Mild Pre-eclampsia 38 294 EM. LSCS         2.5     140 92 2+ 
47 Shalini 26 1735 Primi Mild Pre-eclampsia 40 650 EM. LSCS         3.5     150 80 1+ 
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48 Renuka 24 831 G3P2L2 Mild Pre-eclampsia 40 242 EM. LSCS         2.9     142 94 1+ 
49 Bhuvaneshwari 21 1361 Primi Mild Pre-eclampsia 30 245 LN         1.2     150 100 2+ 
50 Amutha 32 1703 G2P1L1 Controls 38 458 LN         2.8     110 60 NIL 
51 Mekala 21 2406 Primi Controls 39 202 LN         2.7     112 72 Trace 
52 Meenatchi 26 2777 G2P1L1 Controls 40 392 LN         4.1     112 80 NIL 
53 Punithavathi 21 3110 Primi Controls 40 239 LN         3     110 72 NIL 
54 Usha 25 3192 G3P2L2 Controls 38 283 LN         3.2     120 80 NIL 
55 Nirmala 24 3279 G2P1L1 Controls 39 494 LN         2.6     110 82 1+ 
56 Vani 28 5319 Primi Eclampsia 32 1800 LN   1     1.7     200 120 4+ 
57 Nandhini 20 5537 Primi Mild Pre-eclampsia 28 793 Ass Breech     1   1   1 150 90 1+ 
58 Umavathi 21 4046 Primi Severe Pre-eclampsia 34 1098 LN     1   1.5   1 150 114 4+ 
59 Sandhya 23 4278 Primi Severe Pre-eclampsia 37 520 EM. LSCS         2.25     168 120 3+ 
60 Padmavathy 24 4665 G2A1 Severe Pre-eclampsia 34 294 EM. LSCS         2     172 130 3+ 
61 Jaya 20 570 Primi Severe Pre-eclampsia 40 469 EM. LSCS         2.5     160 90 2+ 
62 Padmavathy 23 4786 Primi Severe Pre-eclampsia 35 510 EM. LSCS         2.2     150 110 3+ 
63 Noorbevi 21 6876 Primi Severe Pre-eclampsia 38 284 EM. LSCS         2.75     160 90 1+ 
64 Jayanthi 27 4907 G2A1 Mild Pre-eclampsia 40 637 EM. LSCS         2.75     140 90 1+ 
65 Regina 24 5035 G2P1L1 Mild Pre-eclampsia 39 474 EM. LSCS         3.45     150 90 1+ 
66 Porkodi 24 4578 G4P2L2A1 Mild Pre-eclampsia 34 537 LN         1.75     150 100 2+ 
67 Geetha 25 4788 G3P2L0 Mild Pre-eclampsia 40 653 LN         3.2     140 90 1+ 
68 Suganthi 29 3657 Primi Controls 40 432 LN         3.1     120 70 NIL 
69 Maheshwari 24 4179 G3P2L1 Controls 40 212 LN         3.1     112 72 NIL 
70 Anjali 22 5395 Primi Controls 36 119 LN         3     106 70 Trace 
71 Anandhi 20 5986 Primi Controls 38 183 LN         2.2     120 82 NIL 
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72 Komala 20 6295 Primi Controls 40 284 LN         2.8     122 74 NIL 
73 Anitha 24 6435 G2P1L1 Controls 40 344 LN         2.75     116 80 NIL 
74 Gayathri 23 6713 Primi Controls 39 304 LN         2.9     114 70 Trace 
75 Chitra 23 6989 Primi Controls 37 482 LN         2.5     110 60 NIL 
76 Parvathi 24 7064 G3P2L1A1 Mild Pre-eclampsia 40 345 LN         3.5     140 90 2+ 
77 Jayaseela 26 7128 G2P1L1 Mild Pre-eclampsia 40 423 LN         3.75     150 90 2+ 
78 Shylabanu 20 8268 Primi Eclampsia 30 1892 EM. LSCS   1     1.2     180 126 3+ 
79 Adhilakshmi 23 9286 Primi Mild Pre-eclampsia 38 234 EM. LSCS     1   2.9     140 100 2+ 
80 Lakshmi 30 9982 G2P1L1 Severe Pre-eclampsia 37 1204 EM.Rpt LSCS     1   1.6     160 120 3+ 
81 Sangeetha 28 7608 Primi Mild Pre-eclampsia 32 123 LN     1   1.5     140 100 2+ 
82 Kothainayagi 20 7777 Primi Severe Pre-eclampsia 36 489 EM. LSCS         2.3     160 110 2+ 
83 Ezhilarasi 22 7926 Primi Severe Pre-eclampsia 36 194 EM. LSCS         2.2     168 120 3+ 
84 Indira 27 7232 G2P1L1 Severe Pre-eclampsia 36 182 LN         2.2     170 120 3+ 
85 Saranya 20 7223 Primi Severe Pre-eclampsia 38 389 LN         2.25     160 110 3+ 
86 Prema 26 7229 Primi Mild Pre-eclampsia 35 642 EM. LSCS         2.2     140 90 1+ 
87 Sivashankari 21 8830 Primi Mild Pre-eclampsia 40 203 EM. LSCS         3.25     142 90 1+ 
88 Sumithra 24 50662 Primi Mild Pre-eclampsia 34 230 LN         2.6     150 100 2+ 
89 Deepa 25 14824 G2P1L1 Severe Pre-eclampsia 30 1506 EM. LSCS     1   1.25   1 200 120 3+ 
90 Sathya 23 15108 G3P1L1A1 Severe Pre-eclampsia 32 1530 EM. LSCS     1   1.5   1 180 130 3+ 
91 Vinitha 22 15451 Primi Mild Pre-eclampsia 36 297 EM. LSCS     1   2.14     140 90 2+ 
92 Lakshmi 22 12004 G2P1L1 Severe Pre-eclampsia 38 293 EM. LSCS         2.75     160 90 2+ 
93 Alamelu 27 12818 Primi Severe Pre-eclampsia 39 204 EM. LSCS         2.75     166 80 2+ 
94 Praveena 22 14618 Primi Severe Pre-eclampsia 40 109 LN         2.9     160 82 2+ 
95 Allirani 26 11753 Primi Severe Pre-eclampsia 40 532 LN         2.8     160 90 1+ 
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96 Kaveri 26 11830 Primi Mild Pre-eclampsia 40 432 EM. LSCS         3.7     140 90 1+ 
97 Revathi 22 12460 G2P1L1 Mild Pre-eclampsia 40 345 EM. LSCS         3.45     146 100 1+ 
98 Guna 24 11539 G3P2L3 Mild Pre-eclampsia 34 564 LN         1.5   1 150 100 2+ 
99 Ranjani 20 11787 Primi Mild Pre-eclampsia 40 576 LN         3     140 92 1+ 
100 Mariammal 22 14178 G2P1L1 Controls 36 273 EM. LSCS         2.3     122 80 NIL 
101 Sharmila 24 12350 G2P1L1 Controls 40 282 EM. LSCS         2.7     120 70 NIL 
102 Umaudayavani 22 11491 G2P1L1 Controls 37 183 EM. LSCS         2.5     110 60 NIL 
103 Maria 25 12465 Primi Controls 39 138 LN         3.25     112 60 Trace 
104 Krishnaveni 21 12730 Primi Controls 37 209 LN         2.6     130 70 NIL 
105 Jayalakshmi 29 13316 G2P1L1 Controls 39 308 LN         3.5     120 72 NIL 
106 Sowmya 20 13632 G2A1 Controls 38 401 LN         2.7     112 64 NIL 
107 Renuga 22 14897 Primi Eclampsia 38 723 EM. LSCS   1     2.5     150 100 2+ 
108 Poongodhai 31 19593 Primi Eclampsia 30 3200 EM. LSCS   1   1 1.2     160 120 4+ 
109 Ezhilarasi 23 15137 G2P1L1 Mild Pre-eclampsia 32 689 EM.Rpt LSCS     1   1.5   1 140 90 2+ 
110 Devaki 22 15408 Primi Severe Pre-eclampsia 38 240 LN         3     160 120 3+ 
111 Rekha 22 16084 Primi Mild Pre-eclampsia 40 408 EM. LSCS         3.2     146 92 1+ 
112 Kanvizhi 23 15985 Primi Controls 40 145 EM. LSCS         2.7     120 70 NIL 
113 Subadra 20 16439 Primi Controls 40 132 EM. LSCS         3     110 60 NIL 
114 Manjula 23 23162 Primi Eclampsia 36 909 EM. LSCS   1     2.25     180 100 4+ 
115 Rasathi 23 20844 Primi Eclampsia 38 1030 EM. LSCS   1   1 2.2     160 120 3+ 
116 Sathya 20 23073 Primi Severe Pre-eclampsia 34 900 EM. LSCS     1   2   1 160 130 4+ 
117 Nazreen 25 23840 G2P1L1 Mild Pre-eclampsia 38 644 EM. LSCS     1   2.5   1 146 92 1+ 
118 Lavanya 27 24155 Primi Severe Pre-eclampsia 38 745 EM. LSCS     1   2.8   1 150 110 4+ 
119 Radha 23 23331 Primi Mild Pre-eclampsia 40 302 LN     1   3   1 150 100 2+ 
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120 Pramila 21 23671 Primi Severe Pre-eclampsia 39 1040 LN     1   2.75   1 160 116 4+ 
121 Nathiya 21 22094 Primi Severe Pre-eclampsia 39 209 EM. LSCS         2.2     150 110 3+ 
122 Prema 22 22389 Primi Severe Pre-eclampsia 38 1304 EM. LSCS         2.7   1 156 110 3+ 
123 Premalatha 23 23529 Primi Mild Pre-eclampsia 40 237 EM. LSCS         3.15     140 92 1+ 
124 Manju 25 23834 Primi Mild Pre-eclampsia 40 198 EM. LSCS         3     150 90 1+ 
125 Rohini 20 22280 Primi Mild Pre-eclampsia 38 109 EM. LSCS         2.75     140 92 1+ 
126 Selvi 23 23435 G2P1L1 Mild Pre-eclampsia 39 183 LN         3.25     146 90 2+ 
127 Tamilselvi 18 22275 Primi Mild Pre-eclampsia 40 284 LN         3.4     142 94 1+ 
128 Vinodhini 24 24734 G2P1L0 Controls 40 282 EM. LSCS         3.5     110 70 NIL 
129 Varalakshmi 24 24316 Primi Controls 40 273 EM. LSCS         2.9     120 70 NIL 
130 Sangeetha 20 23721 Primi Controls 39 392 EM. LSCS         3.4     110 60 NIL 
131 Geetha 22 24312 Primi Controls 39 374 LN         3     120 60 NIL 
132 Mariyammal 22 24341 Primi Controls 39 294 LN         3     110 72 NIL 
133 Bhavani 24 24124 G2P1L1 Controls 40 290 LN         3.5     110 68 NIL 
134 Kalayarsi 26 25935 Primi Eclampsia 32 1234 EM. LSCS   1     1.4     150 100 3+ 
135 Jyothi 34 26839 G2P1L1 Eclampsia 39 430 EM.Rpt LSCS   1     3.2     160 110 4+ 
136 Valli 22 26927 G2A1 Eclampsia 32 1049 EM. LSCS   1     1.2     170 110 4+ 
137 Priya 26 28019 Primi Eclampsia 34 1089 EM. LSCS   1     1.6     160 120 4+ 
138 Saroja 25 25542 G3P2L2 Mild Pre-eclampsia 39 367 EM. LSCS     1   3   1 140 96 2+ 
139 Dhanya 23 26219 Primi Severe Pre-eclampsia 36 760 EM. LSCS     1   2.6     180 120 3+ 
140 Anitha Devi 24 26225 G3P2L2 Mild Pre-eclampsia 38 743 EM. LSCS     1   2.5   1 150 96 2+ 
141 Selvi 30 26818 G4P1L1A2 Severe Pre-eclampsia 37 1392 EM. LSCS     1   2.8     190 120 3+ 
142 Deepa 22 27136 Primi Mild Pre-eclampsia 34 543 EM. LSCS     1   1.7     150 92 2+ 
143 Vengammal 26 28121 G3P2L2 Severe Pre-eclampsia 36 753 EM. LSCS     1   1.9     170 126 3+ 
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144 Muthalammal 24 28749 G3P2L2 Severe Pre-eclampsia 38 604 EM. LSCS     1   2.75     150 110 3+ 
145 Aruna 22 29191 G2P1L1 Severe Pre-eclampsia 37 796 EM. LSCS     1   2.25     166 112 4+ 
146 Pushpalatha 28 24918 Primi Mild Pre-eclampsia 34 384 LN         1.5   1 150 92 2+ 
147 Elavarasi 28 24770 G2A1 Mild Pre-eclampsia 34 292 LN         1.5   1 140 100 2+ 
148 Rajeshwari 27 26404 G2P1L1 Severe Pre-eclampsia 37 630 EM. LSCS         1.7 1   180 110 3+ 
149 Shanthakumari 20 25668 Primi Mild Pre-eclampsia 38 128 EM. LSCS         3     140 90 1+ 
150 Anbarasi 25 25122 Primi Mild Pre-eclampsia 39 134 LN         2.7     150 90 1+ 
151 Subha 22 28816 Primi Controls 38 328 EM. LSCS         2.25     110 70 NIL 
152 Shanthi 23 28863 G4A3 Controls 37 284 EM. LSCS         2.5     126 70 NIL 
153 Mariya 30 26107 G3A2 Controls 38 194 EM. LSCS         2.75     122 72 NIL 
154 Sudha 28 25032 Primi Controls 39 104 EM. LSCS         2.5     100 64 NIL 
155 Thilagavathi 29 24711 Primi Controls 40 145 EM. LSCS         3     112 76 NIL 
156 Jyothi 23 29280 Primi Eclampsia 36 1980 EM. LSCS   1     2     160 122 4+ 
157 Kalaimathi 27 29980 Primi Severe Pre-eclampsia 37 333 EM. LSCS         2.5     162 100 2+ 
158 Sathya 22 31040 Primi Severe Pre-eclampsia 37 374 EM. LSCS         2.3     168 90 2+ 
159 Geethalakshmi 24 30497 Primi Severe Pre-eclampsia 38 284 LN         3     170 92 2+ 
160 Amala Mery 29 29274 Primi Mild Pre-eclampsia 38 219 EM. LSCS         2.8     140 100 1+ 
161 Suguna 24 29986 Primi Mild Pre-eclampsia 37 295 EM. LSCS         2.8     150 90 2+ 
162 Savithri 22 30803 Primi Mild Pre-eclampsia 39 284 LN         2.5     140 96 1+ 
163 Kalyani 35 29249 G2P1L1 Mild Pre-eclampsia 40 325 LN         2.7     140 100 1+ 
164 Tamilselvi 24 29337 G2P1L1 Mild Pre-eclampsia 39 276 LN         2.75     148 102 1+ 
165 Prema 26 29315 Primi Controls 36 121 EM. LSCS         2.3     110 72 NIL 
166 Amaravathy 20 30032 G2A1 Controls 40 101 LN         3.3     120 80 1+ 
167 Rajelakshmi 22 30046 G2P1L1 Controls 39 167 LN         3     110 82 NIL 
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168 Anuradha 27 30007 G2P1L0 Controls 40 289 LN         3.4     112 72 NIL 
169 Maheshwari 23 29911 G2P1L1 Controls 36 245 LN         2.4     110 74 NIL 
170 Mahalakshmi 25 29861 G2P1L1 Controls 40 321 LN         3.6     122 84 NIL 
171 Nalini 24 29560 Primi Controls 38 345 LN         2.5     132 82 NIL 
172 Sathya 21 29721 G2A1 Controls 39 432 LN         3     110 76 NIL 
173 Udaya 28 29367 Primi Eclampsia 34 1048 EM. LSCS   1     1.5     160 112 4+ 
 
  
  
 
